{"status": "ok", "message-type": "work-list", "message-version": "1.0.0", "message": {"facets": {}, "total-results": 50, "items": [{"indexed": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T12:31:35Z", "timestamp": 1574253095117}, "reference-count": 13, "publisher": "Springer Science and Business Media LLC", "issue": "1", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2007, 1, 1]], "date-time": "2007-01-01T00:00:00Z", "timestamp": 1167609600000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Nat Rev Drug Discov"], "published-print": {"date-parts": [[2007, 1]]}, "DOI": "10.1038/nrd2227", "type": "journal-article", "created": {"date-parts": [[2006, 12, 29]], "date-time": "2006-12-29T09:33:31Z", "timestamp": 1167384811000}, "page": "21-22", "source": "Crossref", "is-referenced-by-count": 254, "title": ["Vorinostat"], "prefix": "10.1038", "volume": "6", "author": [{"given": "Steven", "family": "Grant", "sequence": "first", "affiliation": []}, {"given": "Chris", "family": "Easley", "sequence": "additional", "affiliation": []}, {"given": "Peter", "family": "Kirkpatrick", "sequence": "additional", "affiliation": []}], "member": "297", "reference": [{"key": "BFnrd2227_CR1", "doi-asserted-by": "publisher", "first-page": "37", "DOI": "10.1038/nrd1930", "volume": "5", "author": "CB Yoo", "year": "2006", "unstructured": "Yoo, C. B. & Jones, P. A. Epigenetic therapy of cancer: past, present and future. Nature Rev. Drug Discov. 5, 37\u201350 (2006).", "journal-title": "Nature Rev. Drug Discov."}, {"key": "BFnrd2227_CR2", "doi-asserted-by": "publisher", "first-page": "769", "DOI": "10.1038/nrd2133", "volume": "5", "author": "JE Bolden", "year": "2006", "unstructured": "Bolden, J. E., Peart, M. J. & Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors. Nature Rev. Drug Discov. 5, 769\u2013784 (2006).", "journal-title": "Nature Rev. Drug Discov."}, {"key": "BFnrd2227_CR3", "doi-asserted-by": "publisher", "first-page": "5705", "DOI": "10.1073/pnas.93.12.5705", "volume": "93", "author": "VM Richon", "year": "1996", "unstructured": "Richon, V. M. et al. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc. Natl Acad. Sci. USA 93, 5705\u20135708 (1996)", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrd2227_CR4", "doi-asserted-by": "publisher", "first-page": "3003", "DOI": "10.1073/pnas.95.6.3003", "volume": "95", "author": "VM Richon", "year": "1998", "unstructured": "Richon, V. M. et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl Acad. Sci. USA 95, 3003\u20133007 (1998).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrd2227_CR5", "first-page": "17174", "volume": "265", "author": "M Yoshida", "year": "1990", "unstructured": "Yoshida, M. et al. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 265, 17174\u201317179 (1990).", "journal-title": "J. Biol. Chem."}, {"key": "BFnrd2227_CR6", "unstructured": "FDA labelling information \n                    [online]\n                    \n                  , (2006)."}, {"key": "BFnrd2227_CR7", "doi-asserted-by": "publisher", "first-page": "150", "DOI": "10.1038/ncponc0106", "volume": "2", "author": "WK Kelly", "year": "2005", "unstructured": "Kelly, W. K. & Marks, P. A. Drug insight: Histone deacetylase inhibitors \u2014 development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nature Clin. Pract. Oncol. 2, 150\u2013157 (2005).", "journal-title": "Nature Clin. Pract. Oncol."}, {"key": "BFnrd2227_CR8", "doi-asserted-by": "publisher", "first-page": "10014", "DOI": "10.1073/pnas.180316197", "volume": "97", "author": "VM Richon", "year": "2000", "unstructured": "Richon, V. M. et al. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl Acad. Sci. USA 97, 10014\u201310019 (2000).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrd2227_CR9", "unstructured": "Duvic, M. et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic Acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 7 Sep 2006 (doi: blood-2006-06-025999v1)."}, {"key": "BFnrd2227_CR10", "doi-asserted-by": "publisher", "first-page": "798", "DOI": "10.1172/JCI24826", "volume": "115", "author": "EJ Kim", "year": "2005", "unstructured": "Kim, E. J. et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J. Clin. Invest. 115, 798\u2013812 (2005).", "journal-title": "J. Clin. Invest."}, {"key": "BFnrd2227_CR11", "doi-asserted-by": "publisher", "first-page": "26729", "DOI": "10.1074/jbc.C500186200", "volume": "280", "author": "P Bali", "year": "2005", "unstructured": "Bali, P. et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J. Biol. Chem. 280, 26729\u201326734 (2005).", "journal-title": "J. Biol. Chem."}, {"key": "BFnrd2227_CR12", "doi-asserted-by": "publisher", "first-page": "241", "DOI": "10.1016/j.ccr.2006.08.009", "volume": "10", "author": "D Trachootham", "year": "2006", "unstructured": "Trachootham, D. et al. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 10, 241\u2013252 (2006).", "journal-title": "Cancer Cell"}, {"key": "BFnrd2227_CR13", "doi-asserted-by": "publisher", "first-page": "673", "DOI": "10.1073/pnas.0408732102", "volume": "102", "author": "JS Ungerstedt", "year": "2005", "unstructured": "Ungerstedt, J. S. et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc. Natl Acad. Sci. USA 102, 673\u2013678 (2005).", "journal-title": "Proc. Natl Acad. Sci. USA"}], "container-title": ["Nature Reviews Drug Discovery"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/nrd2227.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/nrd2227", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/nrd2227.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 3, 17]], "date-time": "2019-03-17T09:33:43Z", "timestamp": 1552815223000}, "score": 24.833977, "issued": {"date-parts": [[2007, 1]]}, "references-count": 13, "journal-issue": {"published-print": {"date-parts": [[2007, 1]]}, "issue": "1"}, "alternative-id": ["BFnrd2227"], "URL": "http://dx.doi.org/10.1038/nrd2227", "relation": {"cites": []}, "ISSN": ["1474-1776", "1474-1784"], "issn-type": [{"value": "1474-1776", "type": "print"}, {"value": "1474-1784", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T10:23:34Z", "timestamp": 1574418214777}, "reference-count": 49, "publisher": "American Society of Hematology", "issue": "22", "content-domain": {"domain": ["ashpublications.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2010, 6, 3]]}, "abstract": "<jats:title>Abstract</jats:title>\n               <jats:p>Interactions between histone deacetylase inhibitors (HDACIs) and the novel proteasome inhibitor carfilzomib (CFZ) were investigated in GC- and activated B-cell\u2013like diffuse large B-cell lymphoma (ABC-DLBCL) cells. Coadministration of subtoxic or minimally toxic concentrations of CFZ) with marginally lethal concentrations of HDACIs (vorinostat, SNDX-275, or SBHA) synergistically increased mitochondrial injury, caspase activation, and apoptosis in both GC- and ABC-DLBCL cells. These events were associated with Jun NH2-terminal kinase (JNK) and p38MAPK activation, abrogation of HDACI-mediated nuclear factor-\u03baB activation, AKT inactivation, Ku70 acetylation, and induction of \u03b3H2A.X. Genetic or pharmacologic JNK inhibition significantly diminished CFZ/vorinostat lethality. CFZ/vorinostat induced pronounced lethality in 3 primary DLBCL specimens but minimally affected normal CD34+ hematopoietic cells. Bortezomib-resistant GC (SUDHL16) and ABC (OCI-LY10) cells exhibited partial cross-resistance to CFZ. However, CFZ/vorinostat dramatically induced resistant cell apoptosis, accompanied by increased JNK activation and \u03b3H2A.X expression. Finally, subeffective vorinostat doses markedly increased CFZ-mediated tumor growth suppression and apoptosis in a murine xenograft OCI-LY10 model. These findings indicate that HDACIs increase CFZ activity in GC- and ABC-DLBCL cells sensitive or resistant to bortezomib through a JNK-dependent mechanism in association with DNA damage and inhibition of nuclear factor-\u03baB activation. Together, they support further investigation of strategies combining CFZ and HDACIs in DLBCL.</jats:p>", "DOI": "10.1182/blood-2009-12-257261", "type": "journal-article", "created": {"date-parts": [[2010, 3, 17]], "date-time": "2010-03-17T01:55:42Z", "timestamp": 1268790942000}, "page": "4478-4487", "update-policy": "http://dx.doi.org/10.1182/blood.2019cm0000", "source": "Crossref", "is-referenced-by-count": 72, "title": ["The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo"], "prefix": "10.1182", "volume": "115", "author": [{"given": "Girija", "family": "Dasmahapatra", "sequence": "first", "affiliation": [{"name": "Department of Medicine, Virginia Commonwealth University Health Systems, Richmond;"}]}, {"given": "Dmitry", "family": "Lembersky", "sequence": "additional", "affiliation": [{"name": "Department of Medicine, Virginia Commonwealth University Health Systems, Richmond;"}]}, {"given": "Lora", "family": "Kramer", "sequence": "additional", "affiliation": [{"name": "Department of Medicine, Virginia Commonwealth University Health Systems, Richmond;"}]}, {"given": "Richard I.", "family": "Fisher", "sequence": "additional", "affiliation": [{"name": "James P. Wilmot Cancer Center, University of Rochester Medical Center, NY; and"}]}, {"given": "Jonathan", "family": "Friedberg", "sequence": "additional", "affiliation": [{"name": "James P. Wilmot Cancer Center, University of Rochester Medical Center, NY; and"}]}, {"given": "Paul", "family": "Dent", "sequence": "additional", "affiliation": [{"name": "Department of Biochemistry and the Massey Cancer Center and Institute for Molecular Medicine, Virginia Commonwealth University Health Systems, Richmond"}]}, {"given": "Steven", "family": "Grant", "sequence": "additional", "affiliation": [{"name": "Department of Medicine, Virginia Commonwealth University Health Systems, Richmond;"}, {"name": "Department of Biochemistry and the Massey Cancer Center and Institute for Molecular Medicine, Virginia Commonwealth University Health Systems, Richmond"}]}], "member": "234", "reference": [{"issue": "9", "key": "2019111722424377800_B1", "doi-asserted-by": "crossref", "first-page": "3183", "DOI": "10.1182/blood-2005-04-1399", "article-title": "Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction.", "volume": "106", "author": "Bea", "year": "2005", "journal-title": "Blood"}, {"issue": "12", "key": "2019111722424377800_B2", "doi-asserted-by": "crossref", "first-page": "1861", "DOI": "10.1084/jem.194.12.1861", "article-title": "Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells.", "volume": "194", "author": "Davis", "year": "2001", "journal-title": "J Exp Med"}, {"issue": "4", "key": "2019111722424377800_B3", "doi-asserted-by": "crossref", "first-page": "235", "DOI": "10.1056/NEJMoa011795", "article-title": "CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.", "volume": "346", "author": "Coiffier", "year": "2002", "journal-title": "N Engl J Med"}, {"issue": "7247", "key": "2019111722424377800_B4", "doi-asserted-by": "crossref", "first-page": "717", "DOI": "10.1038/nature07968", "article-title": "Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.", "volume": "459", "author": "Compagno", "year": "2009", "journal-title": "Nature"}, {"issue": "24", "key": "2019111722424377800_B5", "doi-asserted-by": "crossref", "first-page": "6069", "DOI": "10.1182/blood-2009-01-199679", "article-title": "Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.", "volume": "113", "author": "Dunleavy", "year": "2009", "journal-title": "Blood"}, {"issue": "5", "key": "2019111722424377800_B6", "doi-asserted-by": "crossref", "first-page": "1019", "DOI": "10.1016/j.cell.2009.06.049", "article-title": "Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes.", "volume": "138", "author": "Wang", "year": "2009", "journal-title": "Cell"}, {"issue": "1", "key": "2019111722424377800_B7", "doi-asserted-by": "crossref", "first-page": "377", "DOI": "10.1073/pnas.97.1.377", "article-title": "Molecular mechanism for silencing virally transduced genes involves histone deacetylation and chromatin condensation.", "volume": "97", "author": "Chen", "year": "2000", "journal-title": "Proc Natl Acad Sci U S A"}, {"issue": "9", "key": "2019111722424377800_B8", "doi-asserted-by": "crossref", "first-page": "769", "DOI": "10.1038/nrd2133", "article-title": "Anticancer activities of histone deacetylase inhibitors.", "volume": "5", "author": "Bolden", "year": "2006", "journal-title": "Nat Rev Drug Discov"}, {"issue": "8", "key": "2019111722424377800_B9", "doi-asserted-by": "crossref", "first-page": "4389", "DOI": "10.1073/pnas.0430973100", "article-title": "Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation.", "volume": "100", "author": "Haggarty", "year": "2003", "journal-title": "Proc Natl Acad Sci U S A"}, {"issue": "6", "key": "2019111722424377800_B10", "doi-asserted-by": "crossref", "first-page": "3003", "DOI": "10.1073/pnas.95.6.3003", "article-title": "A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.", "volume": "95", "author": "Richon", "year": "1998", "journal-title": "Proc Natl Acad Sci U S A"}, {"issue": "19", "key": "2019111722424377800_B11", "doi-asserted-by": "crossref", "first-page": "10833", "DOI": "10.1073/pnas.191208598", "article-title": "The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species.", "volume": "98", "author": "Ruefli", "year": "2001", "journal-title": "Proc Natl Acad Sci U S A"}, {"issue": "40", "key": "2019111722424377800_B12", "doi-asserted-by": "crossref", "first-page": "6693", "DOI": "10.1038/sj.onc.1207893", "article-title": "Histone deacetylase inhibitors specifically kill nonproliferating tumour cells.", "volume": "2:23", "author": "Burgess", "year": "2004", "journal-title": "Oncogene"}, {"issue": "1", "key": "2019111722424377800_B13", "doi-asserted-by": "crossref", "first-page": "57", "DOI": "10.1016/j.ccr.2008.12.001", "article-title": "Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis.", "volume": "15", "author": "Fotheringham", "year": "2009", "journal-title": "Cancer Cell"}, {"issue": "4", "key": "2019111722424377800_B14", "doi-asserted-by": "crossref", "first-page": "981", "DOI": "10.1182/blood-2007-10-115873", "article-title": "Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.", "volume": "112", "author": "Garcia-Manero", "year": "2008", "journal-title": "Blood"}, {"issue": "1", "key": "2019111722424377800_B15", "doi-asserted-by": "crossref", "first-page": "21", "DOI": "10.1038/nrd2227", "article-title": "Vorinostat.", "volume": "6", "author": "Grant", "year": "2007", "journal-title": "Nat Rev Drug Discov"}, {"issue": "5", "key": "2019111722424377800_B16", "doi-asserted-by": "crossref", "first-page": "964", "DOI": "10.1093/annonc/mdn031", "article-title": "Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma.", "volume": "19", "author": "Crump", "year": "2008", "journal-title": "Ann Oncol"}, {"issue": "13", "key": "2019111722424377800_B17", "doi-asserted-by": "crossref", "first-page": "6383", "DOI": "10.1158/0008-5472.CAN-06-4086", "article-title": "Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.", "volume": "67", "author": "Demo", "year": "2007", "journal-title": "Cancer Res"}, {"issue": "36", "key": "2019111722424377800_B18", "doi-asserted-by": "crossref", "first-page": "33714", "DOI": "10.1074/jbc.M302559200", "article-title": "Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells.", "volume": "278", "author": "Ling", "year": "2003", "journal-title": "J Biol Chem"}, {"issue": "22", "key": "2019111722424377800_B19", "doi-asserted-by": "crossref", "first-page": "9695", "DOI": "10.1128/MCB.24.22.9695-9704.2004", "article-title": "Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells.", "volume": "24", "author": "Fribley", "year": "2004", "journal-title": "Mol Cell Biol"}, {"issue": "19", "key": "2019111722424377800_B20", "doi-asserted-by": "crossref", "first-page": "16639", "DOI": "10.1074/jbc.M200360200", "article-title": "NF-\u03baB as a therapeutic target in multiple myeloma.", "volume": "277", "author": "Hideshima", "year": "2002", "journal-title": "J Biol Chem"}, {"issue": "12", "key": "2019111722424377800_B21", "doi-asserted-by": "crossref", "first-page": "1062", "DOI": "10.1038/sj.cdd.4400436", "article-title": "Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts.", "volume": "5", "author": "An", "year": "1998", "journal-title": "Cell Death Differ"}, {"issue": "10", "key": "2019111722424377800_B22", "doi-asserted-by": "crossref", "first-page": "2955", "DOI": "10.1158/1078-0432.CCR-06-0170", "article-title": "United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy.", "volume": "12", "author": "Kane", "year": "2006", "journal-title": "Clin Cancer Res"}, {"issue": "30", "key": "2019111722424377800_B23", "doi-asserted-by": "crossref", "first-page": "4867", "DOI": "10.1200/JCO.2006.07.9665", "article-title": "Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.", "volume": "24", "author": "Fisher", "year": "2006", "journal-title": "J Clin Oncol"}, {"issue": "24", "key": "2019111722424377800_B24", "doi-asserted-by": "crossref", "first-page": "6069", "DOI": "10.1182/blood-2009-01-199679", "article-title": "Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.", "volume": "113", "author": "Dunleavy", "year": "2009", "journal-title": "Blood"}, {"issue": "24", "key": "2019111722424377800_B25", "doi-asserted-by": "crossref", "first-page": "2487", "DOI": "10.1056/NEJMoa043445", "article-title": "Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.", "volume": "352", "author": "Richardson", "year": "2005", "journal-title": "N Engl J Med"}, {"issue": "9", "key": "2019111722424377800_B26", "doi-asserted-by": "crossref", "first-page": "3281", "DOI": "10.1182/blood-2007-01-065888", "article-title": "Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.", "volume": "110", "author": "Kuhn", "year": "2007", "journal-title": "Blood"}, {"key": "2019111722424377800_B27", "author": "Jagannath", "year": "2009", "article-title": "Final results of PX-171-003-A0, part 1 of an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM) [abstract].", "journal-title": "ASCO Annual Meeting"}, {"issue": "10", "key": "2019111722424377800_B28", "doi-asserted-by": "crossref", "first-page": "3441", "DOI": "10.1182/blood-2006-04-016055", "article-title": "Aggresome induction by proteasome inhibitor bor-tezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.", "volume": "108", "author": "Catley", "year": "2006", "journal-title": "Blood"}, {"issue": "10", "key": "2019111722424377800_B29", "doi-asserted-by": "crossref", "first-page": "3354", "DOI": "10.1158/1078-0432.CCR-08-2365", "article-title": "PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells.", "volume": "15", "author": "Bhalla", "year": "2009", "journal-title": "Clin Cancer Res"}, {"issue": "2", "key": "2019111722424377800_B30", "doi-asserted-by": "crossref", "first-page": "549", "DOI": "10.1158/1078-0432.CCR-07-1934", "article-title": "Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells.", "volume": "14", "author": "Dai", "year": "2008", "journal-title": "Clin Cancer Res"}, {"issue": "24", "key": "2019111722424377800_B31", "doi-asserted-by": "crossref", "first-page": "11658", "DOI": "10.1158/0008-5472.CAN-05-2370", "article-title": "Bor-tezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis.", "volume": "65", "author": "Nawrocki", "year": "2005", "journal-title": "Cancer Res"}, {"issue": "16", "key": "2019111722424377800_B32", "doi-asserted-by": "crossref", "first-page": "5250", "DOI": "10.1158/1078-0432.CCR-08-2850", "article-title": "Phase I study of vorinostat in combination with bor-tezomib for relapsed and refractory multiple myeloma.", "volume": "15", "author": "Badros", "year": "2009", "journal-title": "Clin Cancer Res"}, {"issue": "9", "key": "2019111722424377800_B33", "doi-asserted-by": "crossref", "first-page": "808", "DOI": "10.4161/cbt.8.9.8131", "article-title": "Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress.", "volume": "8", "author": "Dasmahapatra", "year": "2009", "journal-title": "Cancer Biol Ther"}, {"issue": "1", "key": "2019111722424377800_B34", "doi-asserted-by": "crossref", "first-page": "232", "DOI": "10.1182/blood-2005-06-2302", "article-title": "The tyrphostin adaphostin interacts synergistically with proteasome inhibitors to induce apoptosis in human leukemia cells through a reactive oxygen species (ROS)-dependent mechanism.", "volume": "107", "author": "Dasmahapatra", "year": "2006", "journal-title": "Blood"}, {"issue": "26", "key": "2019111722424377800_B35", "doi-asserted-by": "crossref", "first-page": "5075", "DOI": "10.1016/j.febslet.2007.09.052", "article-title": "RAC3 down-regulation sensitizes human chronic myeloid leukemia cells to TRAIL-induced apoptosis.", "volume": "581", "author": "Colo", "year": "2007", "journal-title": "FEBS Lett"}, {"issue": "13", "key": "2019111722424377800_B36", "doi-asserted-by": "crossref", "first-page": "5429", "DOI": "10.1128/MCB.25.13.5429-5444.2005", "article-title": "Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation.", "volume": "25", "author": "Dai", "year": "2005", "journal-title": "Mol Cell Biol"}, {"issue": "6", "key": "2019111722424377800_B37", "doi-asserted-by": "crossref", "first-page": "2439", "DOI": "10.1182/blood-2008-05-159392", "article-title": "Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells.", "volume": "112", "author": "Dai", "year": "2008", "journal-title": "Blood"}, {"issue": "5569", "key": "2019111722424377800_B38", "doi-asserted-by": "crossref", "first-page": "922", "DOI": "10.1126/science.1069398", "article-title": "Genomic instability in mice lacking histone H2AX.", "volume": "296", "author": "Celeste", "year": "2002", "journal-title": "Science"}, {"issue": "6", "key": "2019111722424377800_B39", "doi-asserted-by": "crossref", "first-page": "2489", "DOI": "10.1182/blood-2007-08-104950", "article-title": "Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein.", "volume": "112", "author": "Oerlemans", "year": "2008", "journal-title": "Blood"}, {"issue": "5", "key": "2019111722424377800_B40", "doi-asserted-by": "crossref", "first-page": "1046", "DOI": "10.1182/blood-2009-01-199604", "article-title": "Bor-tezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.", "volume": "114", "author": "Hideshima", "year": "2009", "journal-title": "Blood"}, {"issue": "29", "key": "2019111722424377800_B41", "doi-asserted-by": "crossref", "first-page": "26729", "DOI": "10.1074/jbc.C500186200", "article-title": "Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.", "volume": "280", "author": "Bali", "year": "2005", "journal-title": "J Biol Chem"}, {"issue": "10", "key": "2019111722424377800_B42", "doi-asserted-by": "crossref", "first-page": "3285", "DOI": "10.1158/1535-7163.MCT-08-0385", "article-title": "Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions.", "volume": "7", "author": "Rosato", "year": "2008", "journal-title": "Mol Cancer Ther"}, {"issue": "24", "key": "2019111722424377800_B43", "doi-asserted-by": "crossref", "first-page": "17330", "DOI": "10.1074/jbc.C700079200", "article-title": "A proteomic analysis of ataxia telangiectasia-mutated (ATM)/ATM-Rad3-related (ATR) substrates identifies the ubiquitin-proteasome system as a regulator for DNA damage checkpoints.", "volume": "282", "author": "Mu", "year": "2007", "journal-title": "J Biol Chem"}, {"issue": "18", "key": "2019111722424377800_B44", "doi-asserted-by": "crossref", "first-page": "8536", "DOI": "10.1158/0008-5472.CAN-07-1166", "article-title": "Inhibitors of the proteasome suppress homologous DNA recombination in mammalian cells.", "volume": "67", "author": "Murakawa", "year": "2007", "journal-title": "Cancer Res"}, {"issue": "5", "key": "2019111722424377800_B45", "doi-asserted-by": "crossref", "first-page": "1409", "DOI": "10.1016/j.jmb.2008.12.015", "article-title": "DNA replication arrest in response to genotoxic stress provokes early activation of stress-activated protein kinases (SAPK/JNK).", "volume": "385", "author": "Damrot", "year": "2009", "journal-title": "J Mol Biol"}, {"issue": "6811", "key": "2019111722424377800_B46", "doi-asserted-by": "crossref", "first-page": "433", "DOI": "10.1038/35044005", "article-title": "The DNA damage response: putting checkpoints in perspective.", "volume": "408", "author": "Zhou", "year": "2000", "journal-title": "Nature"}, {"issue": "3", "key": "2019111722424377800_B47", "doi-asserted-by": "crossref", "first-page": "673", "DOI": "10.1073/pnas.0408732102", "article-title": "Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors.", "volume": "102", "author": "Ungerstedt", "year": "2005", "journal-title": "Proc Natl Acad Sci U S A"}, {"issue": "16", "key": "2019111722424377800_B48", "doi-asserted-by": "crossref", "first-page": "3439", "DOI": "10.1182/blood-2009-05-223677", "article-title": "Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome.", "volume": "114", "author": "Parlati", "year": "2009", "journal-title": "Blood"}, {"issue": "19", "key": "2019111722424377800_B49", "doi-asserted-by": "crossref", "first-page": "4667", "DOI": "10.1182/blood-2008-07-171637", "article-title": "Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.", "volume": "113", "author": "Kuhn", "year": "2009", "journal-title": "Blood"}], "container-title": ["Blood"], "language": "en", "link": [{"URL": "http://ashpublications.org/blood/article-pdf/115/22/4478/1326812/zh802210004478.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "syndication"}, {"URL": "http://ashpublications.org/blood/article-pdf/115/22/4478/1326812/zh802210004478.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 18]], "date-time": "2019-11-18T03:43:18Z", "timestamp": 1574048598000}, "score": 16.799742, "issued": {"date-parts": [[2010, 6, 3]]}, "references-count": 49, "journal-issue": {"published-print": {"date-parts": [[2010, 6, 3]]}, "issue": "22"}, "URL": "http://dx.doi.org/10.1182/blood-2009-12-257261", "relation": {"cites": []}, "ISSN": ["0006-4971", "1528-0020"], "issn-type": [{"value": "0006-4971", "type": "print"}, {"value": "1528-0020", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T04:53:13Z", "timestamp": 1574484793590}, "reference-count": 0, "publisher": "American Association for Cancer Research", "content-domain": {"domain": ["aacrjournals.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2011, 4, 15]]}, "DOI": "10.1158/1538-7445.am2011-2572", "type": "proceedings-article", "created": {"date-parts": [[2012, 6, 27]], "date-time": "2012-06-27T21:12:10Z", "timestamp": 1340831530000}, "update-policy": "http://dx.doi.org/10.1158/aacr-crossmark-policy", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Abstract 2572: The histone deacetylase inhibitors (HDACIs) vorinostat and entinostat interact synergistically with the Bcr/Abl, FLT3, and aurora kinase inhibitor KW-2449 to induce apoptosis in imatininb mesylate (IM)-sensitive and -resistant CML and ALL cellsin vitroandin vivo"], "prefix": "10.1158", "author": [{"given": "Tri K.", "family": "Nguyen", "sequence": "first", "affiliation": []}, {"given": "Elisa", "family": "Attkisson", "sequence": "additional", "affiliation": []}, {"given": "Yun", "family": "Dai", "sequence": "additional", "affiliation": []}, {"given": "Lora", "family": "Kramer", "sequence": "additional", "affiliation": []}, {"given": "Markus", "family": "Muschen", "sequence": "additional", "affiliation": []}, {"given": "Steven", "family": "Grant", "sequence": "additional", "affiliation": []}], "member": "1086", "published-online": {"date-parts": [[2014, 11, 13]]}, "event": {"name": "Proceedings: AACR 102nd Annual Meeting 2011\u2010\u2010 Apr 2\u20106, 2011; Orlando, FL"}, "container-title": ["Experimental and Molecular Therapeutics"], "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/1538-7445.AM2011-2572", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 18]], "date-time": "2019-05-18T21:49:50Z", "timestamp": 1558216190000}, "score": 16.799742, "issued": {"date-parts": [[2011, 4, 15]]}, "references-count": 0, "alternative-id": ["10.1158/1538-7445.AM2011-2572"], "URL": "http://dx.doi.org/10.1158/1538-7445.am2011-2572"}, {"indexed": {"date-parts": [[2019, 12, 5]], "date-time": "2019-12-05T07:19:51Z", "timestamp": 1575530391951}, "reference-count": 0, "publisher": "American Society of Hematology", "issue": "11", "content-domain": {"domain": ["ashpublications.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2007, 11, 16]]}, "abstract": "<jats:title>Abstract</jats:title>\n               <jats:p>MK-0457/VX-680 was developed as a pan-aurora kinase inhibitor that induces apoptosis in tumor cells and suppresses tumor growth in vivo. Recently, it was found that MK-0457 is also a potent inhibitor of both wild type and mutated Bcr/Abl kinases, including the T315I mutant which confers resistance to first- (i.e., imatinib mesylate/IM) and second-generation kinase inhibitors (e.g., dasatinib and nilotinib). Moreover, MK-0457 exhibits significant activity in patients with T315I phenotype-refractory CML or Ph-positive ALL. Here we examined interactions between MK-0457 and the histone deacetylase inhibitor (HDACI) vorinostat/SAHA in Bcr/Abl+ leukemia cells, including those resistant to IM through various mechanisms, particularly the T315I mutation. Co-administration of non- or subtoxic concentrations of vorinostat (0.5\u20132 \u03bcM) increased the lethality of MK-0457 (5\u2013100 nM) in a highly synergistic manner in K562 and LAMA84 cells. Similar interactions were observed in primary CD34+ CML cells, whereas the combination largely spared normal bone marrow mononuclear cells. Moreover, the MK-0457/vorinostat regimen markedly induced cell death in IM-resistant K562 cells exhibiting a Bcr/Abl-independent, Lyn-dependent form of resistance, a phenomenon accompanied by Lyn inactivation. Notably, the regimen was highly active against BaF/3 cells bearing various Bcr/Abl point mutations (i.e., T315I, E255K, and M351T) conferring resistance to IM. These events were associated with inactivation and downregulation of wild type and mutated Bcr/Abl (particularly T315I), reduced expression of phospho-CrkL, and vorinostat-mediated interruption of interactions between Bcr/Abl and Hsp90. Moreover, exposure of cells to marginally toxic doses of MK-0457 resulted in accumulation of cells with greater than 4N DNA content, resulting from induction of endoreduplication. Co-administration of vorinostat strikingly enhanced aurora kinase inhibition by MK-0457, reflected by markedly diminished expression of phospho-histone H3 (Ser 10), accompanied by preferential killing of polyploid cells. Interestingly, vorinostat also interacted with a selective inhibitor of aurora kinase A and B, at concentrations that inhibited histone H3 phosphorylation, to potentiate apoptosis in CML cells without modifying expression of phospho-Bcr/Abl or -CrkL. These results suggest that aurora kinase inhibition plays a functional role in synergistic interactions between HDACI and aurora kinase inhibitors. Finally, vorinostat markedly induced expression of the pro-apoptotic BH3-only protein Bim in various CML cell lines, including BaF/3 cells expressing the T315I Bcr/Abl mutation, as well as in primary CML cells. Knockdown of Bim by siRNA significantly protected K562 cells from apoptosis induced by vorinostat but not MK-0457. Furthermore, siRNA-mediated Bim downregulation blocked induction of Bim expression by vorinostat and dramatically diminished the capacity of this agent to potentiate MK-0457 lethality. In addition, blockade of apoptosis by Bim siRNA did not modify downregulation of Bcr/Abl or phospho-histone H3 in cells exposed to the vorinostat/MK-0457 regimen, arguing against the possibility that the latter phenomena are secondary to activation of apoptotic cascade. Together, these findings indicate that vorinostat dramatically increases MK-0457 lethality in IM-sensitive and -resistant CML cells, and suggest that inactivation of Bcr/Abl kinase and aurora kinases, as well as Bim induction by vorinostat, contribute to this phenomenon.</jats:p>", "DOI": "10.1182/blood.v110.11.1041.1041", "type": "journal-article", "created": {"date-parts": [[2019, 10, 13]], "date-time": "2019-10-13T09:39:11Z", "timestamp": 1570959551000}, "page": "1041-1041", "update-policy": "http://dx.doi.org/10.1182/blood.2019cm0000", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Vorinostat Synergistically Potentiates MK-0457 Lethality in Chronic Myelogenous Leukemia (CML) Cells Sensitive and Resistant to Imatinib Mesylate."], "prefix": "10.1182", "volume": "110", "author": [{"given": "Yun", "family": "Dai", "sequence": "first", "affiliation": [{"name": "Department of Medicine, VCU/Massey Cancer Center, Richmond, VA, USA"}]}, {"given": "Shuang", "family": "Chen", "sequence": "additional", "affiliation": [{"name": "Department of Medicine, VCU/Massey Cancer Center, Richmond, VA, USA"}]}, {"given": "Charis A.", "family": "Venditti", "sequence": "additional", "affiliation": [{"name": "Department of Medicine, VCU/Massey Cancer Center, Richmond, VA, USA"}]}, {"given": "Tri K.", "family": "Nguyen", "sequence": "additional", "affiliation": [{"name": "Department of Medicine, VCU/Massey Cancer Center, Richmond, VA, USA"}]}, {"given": "Paul", "family": "Dent", "sequence": "additional", "affiliation": [{"name": "Department of Medicine, VCU/Massey Cancer Center, Richmond, VA, USA"}]}, {"given": "Steven", "family": "Grant", "sequence": "additional", "affiliation": [{"name": "Department of Medicine, VCU/Massey Cancer Center, Richmond, VA, USA"}]}], "member": "234", "container-title": ["Blood"], "language": "en", "link": [{"URL": "https://ashpublications.org/blood/article/110/11/1041/73694/Vorinostat-Synergistically-Potentiates-MK0457", "content-type": "application/pdf", "content-version": "vor", "intended-application": "syndication"}, {"URL": "https://ashpublications.org/blood/article/110/11/1041/73694/Vorinostat-Synergistically-Potentiates-MK0457", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 17]], "date-time": "2019-11-17T10:49:04Z", "timestamp": 1573987744000}, "score": 16.799742, "issued": {"date-parts": [[2007, 11, 16]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2007, 11, 16]]}, "issue": "11"}, "URL": "http://dx.doi.org/10.1182/blood.v110.11.1041.1041", "ISSN": ["0006-4971", "1528-0020"], "issn-type": [{"value": "0006-4971", "type": "print"}, {"value": "1528-0020", "type": "electronic"}], "subject": ["Immunology", "Cell Biology", "Biochemistry", "Hematology"]}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T21:29:27Z", "timestamp": 1574371767482}, "reference-count": 65, "publisher": "American Society of Hematology", "issue": "3", "content-domain": {"domain": ["ashpublications.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2008, 8, 1]]}, "abstract": "<jats:title>Abstract</jats:title>\n               <jats:p>Interactions between the dual Bcr/Abl and aurora kinase inhibitor MK-0457 and the histone deacetylase inhibitor vorinostat were examined in Bcr/Abl+ leukemia cells, including those resistant to imatinib mesylate (IM), particularly those with the T315I mutation. Coadministration of vorinostat dramatically increased MK-0457 lethality in K562 and LAMA84 cells. Notably, the MK-0457/vorinostat regimen was highly active against primary CD34+ chronic myelogenous leukemia (CML) cells and Ba/F3 cells bearing various Bcr/Abl mutations (ie, T315I, E255K, and M351T), as well as IM-resistant K562 cells exhibiting Bcr/Abl-independent, Lyn-dependent resistance. These events were associated with inactivation and down-regulation of wild-type (wt) and mutated Bcr/Abl (particularly T315I). Moreover, treatment with MK-0457 resulted in accumulation of cells with 4N or more DNA content, whereas coadministration of vorinostat markedly enhanced aurora kinase inhibition by MK-0457, and preferentially killed polyploid cells. Furthermore, vorinostat also interacted with a selective inhibitor of aurora kinase A and B to potentiate apoptosis without modifying Bcr/Abl activity. Finally, vorinostat markedly induced Bim expression, while blockade of Bim induction by siRNA dramatically diminished the capacity of this agent to potentiate MK-0457 lethality. Together, these findings indicate that vorinostat strikingly increases MK-0457 activity against IM-sensitive and -resistant CML cells through inactivation of Bcr/Abl and aurora kinases, as well as by induction of Bim.</jats:p>", "DOI": "10.1182/blood-2007-10-116376", "type": "journal-article", "created": {"date-parts": [[2008, 5, 28]], "date-time": "2008-05-28T03:09:10Z", "timestamp": 1211944150000}, "page": "793-804", "update-policy": "http://dx.doi.org/10.1182/blood.2019cm0000", "source": "Crossref", "is-referenced-by-count": 37, "title": ["Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate"], "prefix": "10.1182", "volume": "112", "author": [{"given": "Yun", "family": "Dai", "sequence": "first", "affiliation": [{"name": "Departments ofMedicine,"}]}, {"given": "Shuang", "family": "Chen", "sequence": "additional", "affiliation": [{"name": "Departments ofMedicine,"}]}, {"given": "Charis A.", "family": "Venditti", "sequence": "additional", "affiliation": [{"name": "Departments ofMedicine,"}]}, {"given": "Xin-Yan", "family": "Pei", "sequence": "additional", "affiliation": [{"name": "Departments ofMedicine,"}]}, {"given": "Tri K.", "family": "Nguyen", "sequence": "additional", "affiliation": [{"name": "Departments ofMedicine,"}]}, {"given": "Paul", "family": "Dent", "sequence": "additional", "affiliation": [{"name": "Biochemistry, and"}]}, {"given": "Steven", "family": "Grant", "sequence": "additional", "affiliation": [{"name": "Departments ofMedicine,"}, {"name": "Biochemistry, and"}, {"name": "Pharmacology, Virginia Commonwealth University/Massey Cancer Center, Richmond"}]}], "member": "234", "reference": [{"key": "2019111800192688800_B1", "author": "Druker", "first-page": "111", "year": "2002", "article-title": "Chronic myelogenous leukemia.", "journal-title": "Hematology Am Soc Hematol Educ Program", "DOI": "10.1182/asheducation-2002.1.111", "doi-asserted-by": "crossref"}, {"key": "2019111800192688800_B2", "doi-asserted-by": "crossref", "first-page": "2038", "DOI": "10.1182/blood.V83.8.2038.2038", "article-title": "Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia.", "volume": "83", "author": "Bedi", "year": "1994", "journal-title": "Blood"}, {"key": "2019111800192688800_B3", "doi-asserted-by": "crossref", "first-page": "2408", "DOI": "10.1056/NEJMoa062867", "article-title": "Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.", "volume": "355", "author": "Druker", "year": "2006", "journal-title": "N Engl J Med"}, {"key": "2019111800192688800_B4", "first-page": "837", "article-title": "Chronic myeloid leukemia: current status and controversies.", "volume": "18", "author": "Mughal", "year": "2004", "journal-title": "Oncology (Williston Park)"}, {"key": "2019111800192688800_B5", "doi-asserted-by": "crossref", "first-page": "645", "DOI": "10.2174/156800906779010209", "article-title": "Mechanisms of resistance to imatinib in CML patients: a paradigm for the advantages and pitfalls of molecularly targeted therapy.", "volume": "6", "author": "Ritchie", "year": "2006", "journal-title": "Curr Cancer Drug Targets"}, {"key": "2019111800192688800_B6", "doi-asserted-by": "crossref", "first-page": "2242", "DOI": "10.1182/blood-2007-03-066936", "article-title": "Bcr-Abl kinase domain mutations, drug resistance and the road to a cure of chronic myeloid leukemia.", "volume": "110", "author": "O'Hare", "year": "2007", "journal-title": "Blood"}, {"key": "2019111800192688800_B7", "doi-asserted-by": "crossref", "first-page": "345", "DOI": "10.1038/nrc2126", "article-title": "Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia.", "volume": "7", "author": "Weisberg", "year": "2007", "journal-title": "Nat Rev Cancer"}, {"key": "2019111800192688800_B8", "doi-asserted-by": "crossref", "first-page": "4500", "DOI": "10.1158/0008-5472.CAN-05-0259", "article-title": "In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.", "volume": "65", "author": "O'Hare", "year": "2005", "journal-title": "Cancer Res"}, {"key": "2019111800192688800_B9", "doi-asserted-by": "crossref", "first-page": "262", "DOI": "10.1038/nm1003", "article-title": "VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo.", "volume": "10", "author": "Harrington", "year": "2004", "journal-title": "Nat Med"}, {"key": "2019111800192688800_B10", "doi-asserted-by": "crossref", "first-page": "1", "DOI": "10.1158/1541-7786.MCR-06-0208", "article-title": "Roles of Aurora kinases in mitosis and tumorigenesis.", "volume": "5", "author": "Fu", "year": "2007", "journal-title": "Mol Cancer Res"}, {"key": "2019111800192688800_B11", "doi-asserted-by": "crossref", "first-page": "323", "DOI": "10.1016/j.canlet.2006.12.004", "article-title": "Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680.", "volume": "251", "author": "Cheetham", "year": "2007", "journal-title": "Cancer Lett"}, {"key": "2019111800192688800_B12", "doi-asserted-by": "crossref", "first-page": "1007", "DOI": "10.1158/0008-5472.CAN-05-2788", "article-title": "Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.", "volume": "66", "author": "Young", "year": "2006", "journal-title": "Cancer Res"}, {"key": "2019111800192688800_B13", "doi-asserted-by": "crossref", "first-page": "11011", "DOI": "10.1073/pnas.0504952102", "article-title": "Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.", "volume": "102", "author": "Carter", "year": "2005", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "2019111800192688800_B14", "doi-asserted-by": "crossref", "first-page": "4996", "DOI": "10.1158/0008-5472.CAN-05-2796", "article-title": "Targeting Aurora kinases for the treatment of prostate cancer.", "volume": "66", "author": "Lee", "year": "2006", "journal-title": "Cancer Res"}, {"key": "2019111800192688800_B15", "doi-asserted-by": "crossref", "first-page": "7668", "DOI": "10.1158/0008-5472.CAN-05-3353", "article-title": "The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function.", "volume": "66", "author": "Gizatullin", "year": "2006", "journal-title": "Cancer Res"}, {"key": "2019111800192688800_B16", "doi-asserted-by": "crossref", "first-page": "192", "DOI": "10.1093/jnci/djk073", "article-title": "With targeted drugs, chronic myelogenous leukemia therapy may follow HIV's model.", "volume": "99", "author": "Tuma", "year": "2007", "journal-title": "J Natl Cancer Inst"}, {"key": "2019111800192688800_B17", "doi-asserted-by": "crossref", "first-page": "2562", "DOI": "10.1172/JCI30890", "article-title": "Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.", "volume": "117", "author": "Shah", "year": "2007", "journal-title": "J Clin Invest"}, {"key": "2019111800192688800_B18", "doi-asserted-by": "crossref", "first-page": "500", "DOI": "10.1182/blood-2006-05-025049", "article-title": "MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation.", "volume": "109", "author": "Giles", "year": "2007", "journal-title": "Blood"}, {"key": "2019111800192688800_B19", "doi-asserted-by": "crossref", "first-page": "437", "DOI": "10.3324/haematol.11248", "article-title": "Targeted therapy and the T315I mutation in Philadelphia-positive leukemias.", "volume": "92", "author": "Soverini", "year": "2007", "journal-title": "Haematologica"}, {"key": "2019111800192688800_B20", "doi-asserted-by": "crossref", "first-page": "1351", "DOI": "10.1038/sj.onc.1210204", "article-title": "Discovery and development of SAHA as an anticancer agent.", "volume": "26", "author": "Marks", "year": "2007", "journal-title": "Oncogene"}, {"key": "2019111800192688800_B21", "doi-asserted-by": "crossref", "first-page": "21", "DOI": "10.1038/nrd2227", "article-title": "Vorinostat.", "volume": "6", "author": "Grant", "year": "2007", "journal-title": "Nat Rev Drug Discov"}, {"key": "2019111800192688800_B22", "doi-asserted-by": "crossref", "first-page": "5541", "DOI": "10.1038/sj.onc.1210620", "article-title": "Histone deacetylase inhibitors: molecular mechanisms of action.", "volume": "26", "author": "Xu", "year": "2007", "journal-title": "Oncogene"}, {"key": "2019111800192688800_B23", "doi-asserted-by": "crossref", "first-page": "8071", "DOI": "10.1073/pnas.0702294104", "article-title": "Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma.", "volume": "104", "author": "Lindemann", "year": "2007", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "2019111800192688800_B24", "doi-asserted-by": "crossref", "first-page": "71", "DOI": "10.1038/nm1160", "article-title": "Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway.", "volume": "11", "author": "Insinga", "year": "2005", "journal-title": "Nat Med"}, {"key": "2019111800192688800_B25", "first-page": "3637", "article-title": "The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1.", "volume": "63", "author": "Rosato", "year": "2003", "journal-title": "Cancer Res"}, {"key": "2019111800192688800_B26", "doi-asserted-by": "crossref", "first-page": "18030", "DOI": "10.1073/pnas.0408345102", "article-title": "Apoptotic and autophagic cell death induced by histone deacetylase inhibitors.", "volume": "101", "author": "Shao", "year": "2004", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "2019111800192688800_B27", "doi-asserted-by": "crossref", "first-page": "313", "DOI": "10.1182/blood-2006-10-050260", "article-title": "Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl\u2013mediated drug resistance.", "volume": "110", "author": "Carew", "year": "2007", "journal-title": "Blood"}, {"key": "2019111800192688800_B28", "doi-asserted-by": "crossref", "first-page": "7832", "DOI": "10.1158/0008-5472.CAN-04-4608", "article-title": "Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effects.", "volume": "65", "author": "Xu", "year": "2005", "journal-title": "Cancer Res"}, {"key": "2019111800192688800_B29", "doi-asserted-by": "crossref", "first-page": "151", "DOI": "10.1016/j.molcel.2006.12.008", "article-title": "An acetylation site in the middle domain of Hsp90 regulates chaperone function.", "volume": "25", "author": "Scroggins", "year": "2007", "journal-title": "Mol Cell"}, {"key": "2019111800192688800_B30", "doi-asserted-by": "crossref", "first-page": "26729", "DOI": "10.1074/jbc.C500186200", "article-title": "Inhibiition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis of antileukemia activity of histone deacetylase inhibitors.", "volume": "280", "author": "Bali", "year": "2005", "journal-title": "J Biol Chem"}, {"key": "2019111800192688800_B31", "first-page": "8420", "article-title": "Coadministration of the heat shock protein 90 antagonist 17-allylamino-17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells.", "volume": "63", "author": "Rahmani", "year": "2003", "journal-title": "Cancer Res"}, {"key": "2019111800192688800_B32", "doi-asserted-by": "crossref", "first-page": "202", "DOI": "10.1196/annals.1391.012", "article-title": "Drugging the cancer chaperone HSP90: Combinatorial therapeutic exploitation of oncogene addiction and tumor stress.", "volume": "1113", "author": "Workman", "year": "2007", "journal-title": "Ann N Y Acad Sci"}, {"key": "2019111800192688800_B33", "first-page": "2118", "article-title": "Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.", "volume": "63", "author": "Yu", "year": "2003", "journal-title": "Cancer Res"}, {"key": "2019111800192688800_B34", "doi-asserted-by": "crossref", "first-page": "5869", "DOI": "10.1158/1078-0432.CCR-06-0980", "article-title": "Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.", "volume": "12", "author": "Fiskus", "year": "2006", "journal-title": "Clin Cancer Res"}, {"key": "2019111800192688800_B35", "first-page": "5126", "article-title": "Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.", "volume": "63", "author": "Nimmanapalli", "year": "2003", "journal-title": "Cancer Res"}, {"key": "2019111800192688800_B36", "doi-asserted-by": "crossref", "first-page": "2069", "DOI": "10.1091/mbc.11.6.2069", "article-title": "Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells.", "volume": "11", "author": "Qiu", "year": "2000", "journal-title": "Mol Biol Cell"}, {"key": "2019111800192688800_B37", "doi-asserted-by": "crossref", "first-page": "321", "DOI": "10.1182/blood.V45.3.321.bloodjournal453321", "article-title": "Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome.", "volume": "45", "author": "Lozzio", "year": "1975", "journal-title": "Blood"}, {"key": "2019111800192688800_B38", "doi-asserted-by": "crossref", "first-page": "34227", "DOI": "10.1074/jbc.M402290200", "article-title": "A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.", "volume": "279", "author": "Dai", "year": "2004", "journal-title": "J Biol Chem"}, {"key": "2019111800192688800_B39", "doi-asserted-by": "crossref", "first-page": "4006", "DOI": "10.1182/blood-2006-09-045039", "article-title": "MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825.", "volume": "109", "author": "Nguyen", "year": "2007", "journal-title": "Blood"}, {"key": "2019111800192688800_B40", "doi-asserted-by": "crossref", "first-page": "1209", "DOI": "10.1038/nbt1005-1209", "article-title": "BIRB-796 is not an effective ABL(T315I) inhibitor.", "volume": "23", "author": "O'Hare", "year": "2005", "journal-title": "Nat Biotechnol"}, {"key": "2019111800192688800_B41", "doi-asserted-by": "crossref", "first-page": "9312", "DOI": "10.1073/pnas.85.23.9312", "article-title": "Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein.", "volume": "85", "author": "Daley", "year": "1988", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "2019111800192688800_B42", "doi-asserted-by": "crossref", "first-page": "2239", "DOI": "10.1158/1078-0432.CCR-05-2282", "article-title": "Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.", "volume": "12", "author": "Nguyen", "year": "2006", "journal-title": "Clin Cancer Res"}, {"key": "2019111800192688800_B43", "doi-asserted-by": "crossref", "first-page": "5429", "DOI": "10.1128/MCB.25.13.5429-5444.2005", "article-title": "Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-{kappa}B activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation.", "volume": "25", "author": "Dai", "year": "2005", "journal-title": "Mol Cell Biol"}, {"key": "2019111800192688800_B44", "doi-asserted-by": "crossref", "first-page": "467", "DOI": "10.4161/cc.2.5.465", "article-title": "An intact NF-kappaB pathway is required for histone deacetylase inhibitor-induced G1 arrest and maturation in U937 human myeloid leukemia cells.", "volume": "2", "author": "Dai", "year": "2003", "journal-title": "Cell Cycle"}, {"key": "2019111800192688800_B45", "doi-asserted-by": "crossref", "first-page": "509", "DOI": "10.1182/blood-2003-12-4121", "article-title": "Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.", "volume": "104", "author": "Dai", "year": "2004", "journal-title": "Blood"}, {"key": "2019111800192688800_B46", "doi-asserted-by": "crossref", "first-page": "690", "DOI": "10.1182/blood.V101.2.690", "article-title": "BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.", "volume": "101", "author": "Donato", "year": "2003", "journal-title": "Blood"}, {"key": "2019111800192688800_B47", "doi-asserted-by": "crossref", "first-page": "417", "DOI": "10.1111/j.1600-0609.2007.00835.x", "article-title": "Establishment and characterization of a novel imatinib-sensitive chronic myeloid leukemia cell line MYL, and an imatinib-resistant subline MYL-R showing overexpression of Lyn.", "volume": "78", "author": "Ito", "year": "2007", "journal-title": "Eur J Haematol"}, {"key": "2019111800192688800_B48", "doi-asserted-by": "crossref", "first-page": "479", "DOI": "10.1016/S1535-6108(02)00074-0", "article-title": "Critical role for Gab2 in transformation by BCR/ABL.", "volume": "1", "author": "Sattler", "year": "2002", "journal-title": "Cancer Cell"}, {"key": "2019111800192688800_B49", "doi-asserted-by": "crossref", "first-page": "807", "DOI": "10.2174/1568026054637719", "article-title": "Progress in the development of selective inhibitors of aurora kinases.", "volume": "5", "author": "Mortlock", "year": "2005", "journal-title": "Curr Top Med Chem"}, {"key": "2019111800192688800_B50", "doi-asserted-by": "crossref", "first-page": "16090", "DOI": "10.1073/pnas.0505585102", "article-title": "Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim.", "volume": "102", "author": "Zhao", "year": "2005", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "2019111800192688800_B51", "doi-asserted-by": "crossref", "first-page": "166", "DOI": "10.1200/JCO.2005.01.9679", "article-title": "Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.", "volume": "24", "author": "O'Connor", "year": "2006", "journal-title": "J Clin Oncol"}, {"key": "2019111800192688800_B52", "doi-asserted-by": "crossref", "first-page": "3041", "DOI": "10.1182/blood-2002-05-1361", "article-title": "BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90.", "volume": "100", "author": "Gorre", "year": "2002", "journal-title": "Blood"}, {"key": "2019111800192688800_B53", "doi-asserted-by": "crossref", "first-page": "57", "DOI": "10.1073/pnas.0609973103", "article-title": "V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors.", "volume": "103", "author": "Grbovic", "year": "2006", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "2019111800192688800_B54", "doi-asserted-by": "crossref", "first-page": "1187", "DOI": "10.1038/nm1127", "article-title": "Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells.", "volume": "10", "author": "Ptasznik", "year": "2004", "journal-title": "Nat Med"}, {"key": "2019111800192688800_B55", "doi-asserted-by": "crossref", "first-page": "1176", "DOI": "10.1038/nature04254", "article-title": "Histone H3 serine 10 phosphorylation by Aurora B causes HP1 dissociation from heterochromatin.", "volume": "438", "author": "Hirota", "year": "2005", "journal-title": "Nature"}, {"key": "2019111800192688800_B56", "doi-asserted-by": "crossref", "first-page": "1550", "DOI": "10.1096/fj.02-1003fje", "article-title": "Tumor cell-selective cytotoxicity by targeting cell cycle checkpoints.", "volume": "17", "author": "Warrener", "year": "2003", "journal-title": "FASEB J"}, {"key": "2019111800192688800_B57", "doi-asserted-by": "crossref", "first-page": "6360", "DOI": "10.1158/0008-5472.CAN-06-3012", "article-title": "Histone deacetylase inhibitors induce premature sister chromatid separation and override the mitotic spindle assembly checkpoint.", "volume": "67", "author": "Magnaghi-Jaulin", "year": "2007", "journal-title": "Cancer Res"}, {"key": "2019111800192688800_B58", "doi-asserted-by": "crossref", "first-page": "2566", "DOI": "10.1101/gad.1455006", "article-title": "A novel histone deacetylase pathway regulates mitosis by modulating Aurora B kinase activity.", "volume": "20", "author": "Li", "year": "2006", "journal-title": "Genes Dev"}, {"key": "2019111800192688800_B59", "first-page": "425", "article-title": "The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells.", "volume": "3", "author": "Zhang", "year": "2004", "journal-title": "Mol Cancer Ther"}, {"key": "2019111800192688800_B60", "doi-asserted-by": "crossref", "first-page": "10508", "DOI": "10.1074/jbc.M512719200", "article-title": "Apoptosis signal-regulating kinase 1 is a direct target of E2F1 and contributes to histone deacetylase inhibitor-induced apoptosis through positive feedback regulation of E2F1 apoptotic activity.", "volume": "281", "author": "Tan", "year": "2006", "journal-title": "J Biol Chem"}, {"key": "2019111800192688800_B61", "doi-asserted-by": "crossref", "first-page": "1773", "DOI": "10.1038/sj.leu.2404760", "article-title": "Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa.", "volume": "21", "author": "Inoue", "year": "2007", "journal-title": "Leukemia"}, {"key": "2019111800192688800_B62", "doi-asserted-by": "crossref", "first-page": "645", "DOI": "10.1182/blood-2005-11-4639", "article-title": "Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl\u2013expressing human leukemia cells.", "volume": "108", "author": "Fiskus", "year": "2006", "journal-title": "Blood"}, {"key": "2019111800192688800_B63", "doi-asserted-by": "crossref", "first-page": "248", "DOI": "10.1128/JVI.01096-06", "article-title": "Epstein-barr virus-induced resistance to drugs that activate the mitotic spindle assembly checkpoint in Burkitt's lymphoma cells.", "volume": "81", "author": "Leao", "year": "2007", "journal-title": "J Virol"}, {"key": "2019111800192688800_B64", "doi-asserted-by": "crossref", "first-page": "9436", "DOI": "10.1158/0008-5472.CAN-05-0972", "article-title": "Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds.", "volume": "65", "author": "Aichberger", "year": "2005", "journal-title": "Cancer Res"}, {"key": "2019111800192688800_B65", "doi-asserted-by": "crossref", "first-page": "6172", "DOI": "10.1128/MCB.24.14.6172-6183.2004", "article-title": "Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors.", "volume": "24", "author": "Kuribara", "year": "2004", "journal-title": "Mol Cell Biol"}], "container-title": ["Blood"], "language": "en", "link": [{"URL": "http://ashpublications.org/blood/article-pdf/112/3/793/1307290/zh801508000793.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "syndication"}, {"URL": "http://ashpublications.org/blood/article-pdf/112/3/793/1307290/zh801508000793.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 18]], "date-time": "2019-11-18T05:19:48Z", "timestamp": 1574054388000}, "score": 15.499834, "issued": {"date-parts": [[2008, 8, 1]]}, "references-count": 65, "journal-issue": {"published-print": {"date-parts": [[2008, 8, 1]]}, "issue": "3"}, "URL": "http://dx.doi.org/10.1182/blood-2007-10-116376", "relation": {"cites": []}, "ISSN": ["0006-4971", "1528-0020"], "issn-type": [{"value": "0006-4971", "type": "print"}, {"value": "1528-0020", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T08:03:22Z", "timestamp": 1574496202921}, "reference-count": 0, "publisher": "American Association for Cancer Research", "content-domain": {"domain": ["aacrjournals.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2012, 4, 15]]}, "DOI": "10.1158/1538-7445.am2012-4102", "type": "proceedings-article", "created": {"date-parts": [[2012, 8, 9]], "date-time": "2012-08-09T22:39:16Z", "timestamp": 1344551956000}, "update-policy": "http://dx.doi.org/10.1158/aacr-crossmark-policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Abstract 4102: Histone deacetylase inhibitor, vorinostat, decreases transcription of survivin and is an enhancer of gemcitabine therapy for resistant pancreatic tumors"], "prefix": "10.1158", "author": [{"given": "Leila J.", "family": "Green", "sequence": "first", "affiliation": []}, {"given": "Nadezhda V.", "family": "Koshkina", "sequence": "additional", "affiliation": []}, {"given": "Steven A.", "family": "Curley", "sequence": "additional", "affiliation": []}], "member": "1086", "published-online": {"date-parts": [[2014, 11, 21]]}, "event": {"name": "Proceedings: AACR 103rd Annual Meeting 2012\u2010\u2010 Mar 31\u2010Apr 4, 2012; Chicago, IL"}, "container-title": ["Molecular and Cellular Biology"], "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/1538-7445.AM2012-4102", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 18]], "date-time": "2019-05-18T19:08:39Z", "timestamp": 1558206519000}, "score": 15.156061, "issued": {"date-parts": [[2012, 4, 15]]}, "references-count": 0, "alternative-id": ["10.1158/1538-7445.AM2012-4102"], "URL": "http://dx.doi.org/10.1158/1538-7445.am2012-4102"}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T04:46:17Z", "timestamp": 1574311577517}, "reference-count": 0, "publisher": "American Association for Cancer Research (AACR)", "issue": "14", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Clinical Cancer Research"], "published-print": {"date-parts": [[2007, 7, 15]]}, "DOI": "10.1158/1078-0432.ccr-07-0835", "type": "journal-article", "created": {"date-parts": [[2007, 7, 19]], "date-time": "2007-07-19T00:27:07Z", "timestamp": 1184804827000}, "page": "4280-4290", "source": "Crossref", "is-referenced-by-count": 43, "title": ["Synergistic Interactions between Vorinostat and Sorafenib in Chronic Myelogenous Leukemia Cells Involve Mcl-1 and p21CIP1 Down-Regulation"], "prefix": "10.1158", "volume": "13", "author": [{"given": "G.", "family": "Dasmahapatra", "sequence": "first", "affiliation": []}, {"given": "N.", "family": "Yerram", "sequence": "additional", "affiliation": []}, {"given": "Y.", "family": "Dai", "sequence": "additional", "affiliation": []}, {"given": "P.", "family": "Dent", "sequence": "additional", "affiliation": []}, {"given": "S.", "family": "Grant", "sequence": "additional", "affiliation": []}], "member": "1086", "published-online": {"date-parts": [[2007, 7, 18]]}, "container-title": ["Clinical Cancer Research"], "language": "en", "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/1078-0432.CCR-07-0835", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2016, 12, 23]], "date-time": "2016-12-23T04:20:38Z", "timestamp": 1482466838000}, "score": 14.328697, "issued": {"date-parts": [[2007, 7, 15]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2007, 7, 18]]}, "published-print": {"date-parts": [[2007, 7, 15]]}, "issue": "14"}, "URL": "http://dx.doi.org/10.1158/1078-0432.ccr-07-0835", "ISSN": ["1078-0432", "1557-3265"], "issn-type": [{"value": "1078-0432", "type": "print"}, {"value": "1557-3265", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T02:39:51Z", "timestamp": 1574303991824}, "reference-count": 54, "publisher": "American Society for Pharmacology & Experimental Therapeutics (ASPET)", "issue": "2", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Mol Pharmacol"], "published-print": {"date-parts": [[2009, 8]]}, "DOI": "10.1124/mol.109.056523", "type": "journal-article", "created": {"date-parts": [[2009, 5, 30]], "date-time": "2009-05-30T01:43:36Z", "timestamp": 1243647816000}, "page": "342-355", "source": "Crossref", "is-referenced-by-count": 50, "title": ["Sorafenib and Vorinostat Kill Colon Cancer Cells by CD95-Dependent and -Independent Mechanisms"], "prefix": "10.1124", "volume": "76", "author": [{"given": "Teneille", "family": "Walker", "sequence": "first", "affiliation": []}, {"given": "Clint", "family": "Mitchell", "sequence": "additional", "affiliation": []}, {"given": "Margaret A.", "family": "Park", "sequence": "additional", "affiliation": []}, {"given": "Adly", "family": "Yacoub", "sequence": "additional", "affiliation": []}, {"given": "Martin", "family": "Graf", "sequence": "additional", "affiliation": []}, {"given": "Mohamed", "family": "Rahmani", "sequence": "additional", "affiliation": []}, {"given": "Peter J.", "family": "Houghton", "sequence": "additional", "affiliation": []}, {"given": "Christina", "family": "Voelkel-Johnson", "sequence": "additional", "affiliation": []}, {"given": "Steven", "family": "Grant", "sequence": "additional", "affiliation": []}, {"given": "Paul", "family": "Dent", "sequence": "additional", "affiliation": []}], "member": "36", "published-online": {"date-parts": [[2009, 5, 29]]}, "reference": [{"key": "2019081413565547000_76.2.342.1", "DOI": "10.1038/ncb1005", "doi-asserted-by": "publisher"}, {"key": "2019081413565547000_76.2.342.2", "DOI": "10.1158/1078-0432.CCR-05-0344", "doi-asserted-by": "publisher"}, {"key": "2019081413565547000_76.2.342.3", "DOI": "10.1016/S1044-5323(03)00031-9", "doi-asserted-by": "publisher"}, {"key": "2019081413565547000_76.2.342.4", "DOI": "10.1158/1078-0432.CCR-07-0835", "doi-asserted-by": "publisher"}, {"key": "2019081413565547000_76.2.342.5", "DOI": "10.1158/1535-7163.MCT-07-0231", "doi-asserted-by": "publisher"}, {"key": "2019081413565547000_76.2.342.6", "unstructured": "Dent P (2005) MAP kinase pathways in the control of hepatocyte growth, metabolism and survival, in Signaling Pathways in Liver Diseases (DuFour JF, Clavien PA eds) pp 223-238, Springer, New York.", "DOI": "10.1007/3-540-27194-5_19", "doi-asserted-by": "crossref"}, {"key": "2019081413565547000_76.2.342.7", "DOI": "10.1038/sj.onc.1206701", "doi-asserted-by": "publisher"}, {"key": "2019081413565547000_76.2.342.8", "DOI": "10.1586/14737140.7.5.617", "doi-asserted-by": "publisher"}, {"key": "2019081413565547000_76.2.342.9", "DOI": "10.1016/j.tcb.2005.04.006", "doi-asserted-by": "publisher"}, {"key": "2019081413565547000_76.2.342.10", "volume": "4", "first-page": "167", "year": "2005", "journal-title": "Clin Genitourin Cancer", "DOI": "10.3816/CGC.2005.n.028", "doi-asserted-by": "crossref"}, {"key": "2019081413565547000_76.2.342.11", "DOI": "10.1158/1078-0432.CCR-0001-4", "doi-asserted-by": "publisher"}, {"key": "2019081413565547000_76.2.342.12", "DOI": "10.1006/excr.2001.5187", "doi-asserted-by": "publisher"}, {"key": "2019081413565547000_76.2.342.13", "DOI": "10.1586/17474124.2.1.135", "doi-asserted-by": "publisher"}, {"key": "2019081413565547000_76.2.342.14", "DOI": "10.1038/sj.onc.1205348", "doi-asserted-by": "publisher"}, {"key": "2019081413565547000_76.2.342.15", "DOI": "10.1158/0008-5472.CAN-07-6656", "doi-asserted-by": "publisher"}, {"key": "2019081413565547000_76.2.342.16", "DOI": "10.1038/sj.onc.1206702", "doi-asserted-by": "publisher"}, {"key": "2019081413565547000_76.2.342.17", "DOI": "10.1093/emboj/cdg315", "doi-asserted-by": "publisher"}, {"key": "2019081413565547000_76.2.342.18", "DOI": "10.1016/S0304-3835(98)00201-8", "doi-asserted-by": "publisher"}, {"key": "2019081413565547000_76.2.342.19", "DOI": "10.1074/jbc.M106699200", "doi-asserted-by": "publisher"}, {"key": "2019081413565547000_76.2.342.20", "DOI": "10.1074/jbc.M301010200", "doi-asserted-by": "publisher"}, {"key": "2019081413565547000_76.2.342.21", "volume": "8", "first-page": "452", "year": "2007", "journal-title": "Curr Opin Investig Drugs"}, {"key": "2019081413565547000_76.2.342.22", "DOI": "10.1128/MCB.24.24.10844-10856.2004", "doi-asserted-by": "publisher"}, {"key": "2019081413565547000_76.2.342.23", "DOI": "10.1016/S1471-4892(03)00084-5", "doi-asserted-by": "publisher"}, {"key": "2019081413565547000_76.2.342.24", "DOI": "10.1124/mol.108.047365", "doi-asserted-by": "publisher"}, {"key": "2019081413565547000_76.2.342.25", "DOI": "10.1158/1535-7163.MCT-06-0532", "doi-asserted-by": "publisher"}, {"key": "2019081413565547000_76.2.342.26", "DOI": "10.1002/jcp.10245", "doi-asserted-by": "publisher"}, {"key": "2019081413565547000_76.2.342.27", "DOI": "10.1073/pnas.0709443104", "doi-asserted-by": "publisher"}, {"key": "2019081413565547000_76.2.342.28", "DOI": "10.1038/nrc1411", "doi-asserted-by": "publisher"}, {"key": "2019081413565547000_76.2.342.29", "DOI": "10.1016/j.bbrc.2005.11.131", "doi-asserted-by": "publisher"}, {"key": "2019081413565547000_76.2.342.30", "DOI": "10.1159/000111705", "doi-asserted-by": "publisher"}, {"key": "2019081413565547000_76.2.342.31", "DOI": "10.1124/mol.107.042697", "doi-asserted-by": "publisher"}, {"key": "2019081413565547000_76.2.342.32", "DOI": "10.4161/cbt.7.10.6623", "doi-asserted-by": "publisher"}, {"key": "2019081413565547000_76.2.342.33", "DOI": "10.1158/1535-7163.MCT-08-0400", "doi-asserted-by": "publisher"}, {"key": "2019081413565547000_76.2.342.34", "DOI": "10.3322/canjclin.55.2.74", "doi-asserted-by": "publisher"}, {"key": "2019081413565547000_76.2.342.35", "volume": "33", "first-page": "325", "year": "2008", "journal-title": "Int J Oncol"}, {"key": "2019081413565547000_76.2.342.36", "DOI": "10.1128/MCB.23.9.3052-3066.2003", "doi-asserted-by": "publisher"}, {"key": "2019081413565547000_76.2.342.37", "DOI": "10.1091/mbc.12.9.2629", "doi-asserted-by": "publisher"}, {"key": "2019081413565547000_76.2.342.38", "DOI": "10.1053/jhep.2002.32533", "doi-asserted-by": "publisher"}, {"key": "2019081413565547000_76.2.342.39", "DOI": "10.1074/jbc.M506551200", "doi-asserted-by": "publisher"}, {"key": "2019081413565547000_76.2.342.40", "DOI": "10.1128/MCB.01080-06", "doi-asserted-by": "publisher"}, {"key": "2019081413565547000_76.2.342.41", "DOI": "10.1124/mol.106.033308", "doi-asserted-by": "publisher"}, {"key": "2019081413565547000_76.2.342.42", "DOI": "10.1517/14656566.7.4.453", "doi-asserted-by": "publisher"}, {"key": "2019081413565547000_76.2.342.43", "DOI": "10.1358/dot.2005.41.12.937959", "doi-asserted-by": "publisher"}, {"key": "2019081413565547000_76.2.342.44", "DOI": "10.1158/1535-7163.MCT-06-0596", "doi-asserted-by": "publisher"}, {"key": "2019081413565547000_76.2.342.45", "DOI": "10.1002/cncr.22652", "doi-asserted-by": "publisher"}, {"key": "2019081413565547000_76.2.342.46", "DOI": "10.1074/jbc.M706666200", "doi-asserted-by": "publisher"}, {"key": "2019081413565547000_76.2.342.47", "DOI": "10.1158/1078-0432.CCR-07-0665", "doi-asserted-by": "publisher"}, {"key": "2019081413565547000_76.2.342.48", "DOI": "10.1016/j.molcel.2008.06.001", "doi-asserted-by": "publisher"}, {"key": "2019081413565547000_76.2.342.49", "DOI": "10.1038/onc.2008.468", "doi-asserted-by": "publisher"}, {"key": "2019081413565547000_76.2.342.50", "DOI": "10.1002/bdrb.20104", "doi-asserted-by": "publisher"}, {"key": "2019081413565547000_76.2.342.51", "DOI": "10.1158/1535-7163.MCT-07-2166", "doi-asserted-by": "publisher"}, {"key": "2019081413565547000_76.2.342.52", "DOI": "10.1038/sj.leu.2403868", "doi-asserted-by": "publisher"}, {"key": "2019081413565547000_76.2.342.53", "volume": "2", "first-page": "544", "year": "2003", "journal-title": "Cancer Biol Ther", "DOI": "10.4161/cbt.2.5.454", "doi-asserted-by": "crossref"}, {"key": "2019081413565547000_76.2.342.54", "DOI": "10.1158/1078-0432.CCR-08-0469", "doi-asserted-by": "publisher"}], "container-title": ["Molecular Pharmacology"], "language": "en", "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1124/mol.109.056523", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 8, 14]], "date-time": "2019-08-14T21:01:52Z", "timestamp": 1565816512000}, "score": 14.122606, "issued": {"date-parts": [[2009, 5, 29]]}, "references-count": 54, "journal-issue": {"published-online": {"date-parts": [[2009, 7, 20]]}, "published-print": {"date-parts": [[2009, 8]]}, "issue": "2"}, "alternative-id": ["10.1124/mol.109.056523"], "URL": "http://dx.doi.org/10.1124/mol.109.056523", "relation": {"cites": []}, "ISSN": ["0026-895X", "1521-0111"], "issn-type": [{"value": "0026-895X", "type": "print"}, {"value": "1521-0111", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 24]], "date-time": "2019-11-24T07:23:01Z", "timestamp": 1574580181278}, "reference-count": 0, "publisher": "SAGE Publications", "issue": "2_suppl", "license": [{"URL": "http://journals.sagepub.com/page/policies/text-and-data-mining-license", "start": {"date-parts": [[2012, 8, 1]], "date-time": "2012-08-01T00:00:00Z", "timestamp": 1343779200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": ["journals.sagepub.com"], "crossmark-restriction": true}, "short-container-title": ["Otolaryngol Head Neck Surg"], "published-print": {"date-parts": [[2012, 8]]}, "DOI": "10.1177/0194599812451426a221", "type": "journal-article", "created": {"date-parts": [[2015, 2, 6]], "date-time": "2015-02-06T00:53:02Z", "timestamp": 1423183982000}, "page": "P195-P195", "update-policy": "http://dx.doi.org/10.1177/sage-journals-update-policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Pulmonary Papillomatosis: HPV11 Mutation and Vorinostat Therapy"], "prefix": "10.1177", "volume": "147", "author": [{"given": "Jennifer A.", "family": "Woo", "sequence": "first", "affiliation": []}, {"given": "Hang", "family": "Yuan", "sequence": "additional", "affiliation": []}, {"given": "Xuefeng", "family": "Liu", "sequence": "additional", "affiliation": []}, {"given": "Richard", "family": "Schlegel", "sequence": "additional", "affiliation": []}, {"given": "Nazaneen", "family": "Grant", "sequence": "additional", "affiliation": []}, {"given": "Earl", "family": "Harley", "sequence": "additional", "affiliation": []}, {"given": "Scott", "family": "Myers", "sequence": "additional", "affiliation": []}], "member": "179", "published-online": {"date-parts": [[2012, 8, 21]]}, "container-title": ["Otolaryngology\u2013Head and Neck Surgery"], "language": "en", "link": [{"URL": "http://journals.sagepub.com/doi/pdf/10.1177/0194599812451426a221", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://journals.sagepub.com/doi/pdf/10.1177/0194599812451426a221", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 3, 28]], "date-time": "2019-03-28T09:48:25Z", "timestamp": 1553766505000}, "score": 13.046236, "issued": {"date-parts": [[2012, 8]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2012, 8, 21]]}, "published-print": {"date-parts": [[2012, 8]]}, "issue": "2_suppl"}, "alternative-id": ["10.1177/0194599812451426a221"], "URL": "http://dx.doi.org/10.1177/0194599812451426a221", "ISSN": ["0194-5998", "1097-6817"], "issn-type": [{"value": "0194-5998", "type": "print"}, {"value": "1097-6817", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 12, 5]], "date-time": "2019-12-05T06:47:55Z", "timestamp": 1575528475900}, "reference-count": 0, "publisher": "American Society of Hematology", "issue": "21", "content-domain": {"domain": ["ashpublications.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2013, 11, 15]]}, "abstract": "<jats:title>Abstract</jats:title>\n               <jats:p>Histone deacetylase (e.g., vorinostat) and proteasome inhibitors interact synergistically to promote cell death in various cancer cells, including malignant human hematopoietic cells. The novel, proteasome inhibitor carfilzomib is an attractive candidate for combination regimens due to diminished neurotoxicity, irreversible proteasome inhibition, favorable tolerability profile relative to bortezomib, and preclinical and clinical evidence of activity in bortezomib-resistant cells and patients. Preclinical studies demonstrated synergistic interactions between carfilzomib and vorinostat in human diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells both in vitro and in vivo as well as in bortezomib-resistant cells (Dasmahapatra et al., Blood 115:4478; 2010; Mol Cancer Ther 10:1686, 2001). These preclinical findings prompted a phase 1 trial, using a 3+3 design, with the goal of determining the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) for the combination of carfilzomib and vorinostat in patients with recurrent or refractory B-cell lymphomas.</jats:p>\n               <jats:p>Eligible patients included those with recurrent or refractory non-Hodgkin\u2019s lymphoma. The schedule of administration was vorinostat orally twice-daily on days 1, 2, 3, 8, 9, 10, 15, 16, and 17 followed by carfilzomib as a 30-minute infusion on days 1, 2, 8, 9, 15, and 16 on a 28-day cycle, with indefinite continuation for patients experiencing responses or stable disease. Initial dose levels were 20/27 mg/m2 (carfilzomib) and 200 mg (vorinostat).</jats:p>\n               <jats:p>To date, 20 patients have been treated at 4 dose levels. Patient characteristics included the following disease types: DLBCL, n = 6; follicular lymphoma, n = 2; MCL, n = 10; and transformed lymphoma, n = 2. The male to female ratio was 14:6, the median age was 67 years (range: 36-79), ECOG performance scores ranged from 0 to 2, and the median number of prior therapies was 3.5 (range: 1-13).</jats:p>\n               <jats:p>Dose-limiting toxicities (DLTs) and adverse events were determined using CTCAE version 4. Grade 3 and 4 AEs possibly, probably, or definitely related to study treatment occurring in \u2265 5% of patients included anemia (grade 3, 15%), leukopenia (grade 4, 10%; grade 3, 15%), lymphopenia (grade 3, 10%), neutropenia (grade 4, 5%; grade 3, 25%), thrombocytopenia (grade 3, 10%), catheter-related infection (grade 3, 5%), dyspnea (grade 3, 5%), fatigue (grade 3, 5%), febrile neutropenia (grade 3, 5%), hypokalemia (grade 3, 5%), hyponatremia (grade 3, 5%), lymph node pain (grade 3, 5%), and pneumonitis (grade 3, 5%). Two grade 5 events were observed; 1 was attributed to disease progression and not related to study treatment; 1 was attributed to pneumonia possibly related to treatment. Common grade 2 AEs possibly, probably or definitely related to treatment in \u2265 15% of patients included anemia (25%), diarrhea (15%), fatigue (20%), hyperglycemia (15%), hypokalemia (15%), nausea (15%), neutropenia (15%), thrombocytopenia (20%), and vomiting (15%).</jats:p>\n               <jats:p>There were 2 DLTs at dose level 1, grade 3 pneumonitis and febrile neutropenia, and there were no DLTs at dose level -1 (carfilzomib 20/20 mg/m2 and vorinostat 100 mg twice daily). Two intermediate dose levels (-1a and -1b) were added between dose-levels 1 and -1. No DLTs or significant differences in toxicities were observed at dose levels -1a and -1b. Consequently, two MTD/RP2D levels have been identified: carfilzomib 20/20 mg/m2 and vorinostat 200 mg twice daily (level -1a) and carfilzomib 20/27 mg/m2 and vorinostat 100 mg twice daily (level -1b).</jats:p>\n               <jats:p>All 20 patients treated were evaluable for response. The best response on this phase 1 study was 1 partial response; 2 patients had stable disease.</jats:p>\n               <jats:p>Correlative studies evaluating pre- and post-treatment plasma levels of IL-10 and TNF are currently undergoing analysis.</jats:p>\n               <jats:p>Collectively, these findings indicate that the combination of carfilzomib and vorinostat is reasonably tolerable in this patient population. Two dose levels have been identified for the MTD/RP2D. The regimen appears to have modest activity in heavily pre-treated patients with relapsed and/or refractory B-cell lymphomas.</jats:p>\n               <jats:sec>\n                  <jats:title>Disclosures:</jats:title>\n                  <jats:p>Friedberg: Merck &amp; Co.: Research Funding.</jats:p>\n               </jats:sec>", "DOI": "10.1182/blood.v122.21.4375.4375", "type": "journal-article", "created": {"date-parts": [[2019, 10, 10]], "date-time": "2019-10-10T22:05:09Z", "timestamp": 1570745109000}, "page": "4375-4375", "update-policy": "http://dx.doi.org/10.1182/blood.2019cm0000", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Phase I Trial Of Carfilzomib In Combination With Vorinostat (SAHA) In Patients With Relapsed/Refractory B-Cell Lymphomas"], "prefix": "10.1182", "volume": "122", "author": [{"given": "Beata", "family": "Holkova", "sequence": "first", "affiliation": [{"name": "Virginia Commonwealth University, Massey Cancer Center, Richmond, VA, USA,"}]}, {"given": "Maciej", "family": "Kmieciak", "sequence": "additional", "affiliation": [{"name": "Virginia Commonwealth University, Massey Cancer Center, Richmond, VA, USA,"}]}, {"given": "Prithviraj", "family": "Bose", "sequence": "additional", "affiliation": [{"name": "Virginia Commonwealth University, Massey Cancer Center, Richmond, VA, USA,"}]}, {"given": "Paul M.", "family": "Barr", "sequence": "additional", "affiliation": [{"name": "University of Rochester, James P.Wilmot Cancer Center, Rochester, NY, USA,"}]}, {"given": "Mary Beth", "family": "Tombes", "sequence": "additional", "affiliation": [{"name": "Virginia Commonwealth University, Massey Cancer Center, Richmond, VA, USA,"}]}, {"given": "Ellen", "family": "Shrader", "sequence": "additional", "affiliation": [{"name": "Virginia Commonwealth University, Massey Cancer Center, Richmond, VA, USA,"}]}, {"given": "Erin", "family": "Cebula", "sequence": "additional", "affiliation": [{"name": "University of Rochester, James P. Wilmot Cancer Center, Rochester, NY, USA,"}]}, {"given": "Emily", "family": "Pierce", "sequence": "additional", "affiliation": [{"name": "University of Rochester, James P. Wilmot Cancer Center, Rochester, NY, USA,"}]}, {"given": "Megan M.", "family": "Herr", "sequence": "additional", "affiliation": [{"name": "University of Rochester, James P. Wilmot Cancer Center, Rochester, NY, USA,"}]}, {"given": "Heidi", "family": "Sankala", "sequence": "additional", "affiliation": [{"name": "Virginia Commonwealth University, Massey Cancer Center, Richmond, VA, USA,"}]}, {"given": "Changyong", "family": "Feng", "sequence": "additional", "affiliation": [{"name": "University of Rochester, Rochester, NY, USA"}]}, {"given": "Richard I", "family": "Fisher", "sequence": "additional", "affiliation": [{"name": "University of Rochester, James P. Wilmot Cancer Center, Rochester, NY, USA,"}]}, {"given": "Steven", "family": "Grant", "sequence": "additional", "affiliation": [{"name": "Virginia Commonwealth University, Massey Cancer Center, Richmond, VA, USA,"}]}, {"given": "Jonathan W.", "family": "Friedberg", "sequence": "additional", "affiliation": [{"name": "University of Rochester, James P. Wilmot Cancer Center, Rochester, NY, USA,"}]}], "member": "234", "container-title": ["Blood"], "language": "en", "link": [{"URL": "https://ashpublications.org/blood/article/122/21/4375/13794/Phase-I-Trial-Of-Carfilzomib-In-Combination-With", "content-type": "application/pdf", "content-version": "vor", "intended-application": "syndication"}, {"URL": "https://ashpublications.org/blood/article/122/21/4375/13794/Phase-I-Trial-Of-Carfilzomib-In-Combination-With", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 16]], "date-time": "2019-11-16T11:08:33Z", "timestamp": 1573902513000}, "score": 12.713752, "issued": {"date-parts": [[2013, 11, 15]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2013, 11, 15]]}, "issue": "21"}, "URL": "http://dx.doi.org/10.1182/blood.v122.21.4375.4375", "ISSN": ["0006-4971", "1528-0020"], "issn-type": [{"value": "0006-4971", "type": "print"}, {"value": "1528-0020", "type": "electronic"}], "subject": ["Immunology", "Cell Biology", "Biochemistry", "Hematology"]}, {"indexed": {"date-parts": [[2019, 12, 5]], "date-time": "2019-12-05T06:36:23Z", "timestamp": 1575527783094}, "reference-count": 0, "publisher": "American Society of Hematology", "issue": "21", "content-domain": {"domain": ["ashpublications.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2012, 11, 16]]}, "abstract": "<jats:title>Abstract</jats:title>\n               <jats:p>Abstract 2004</jats:p>\n               <jats:sec>\n                  <jats:title>Introduction:</jats:title>\n                  <jats:p>Autologous hematopoietic stem cell transplantation (HSCT) cures fewer than half of patients with aggressive non-Hodgkin's lymphoma (NHL). Vorinostat (SAHA, Zolinza) has shown activity in relapsed lymphoma and there is preclinical evidence that HDACs may render lymphoma cells more susceptible to host immune killing. We hypothesized that histone acetylation with Vorinostat post transplant would limit relapse by targeting minimal residual disease and improve the capacity of the innate and adaptive immune systems to maintain remissions.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Methods:</jats:title>\n                  <jats:p>The primary objective was to assess safety and tolerability of Vorinostat after BEAM-conditioned autologous peripheral blood stem cell transplant starting day +60 for 21 consecutive days of a 28-day cycle for up to 11 cycles with 4 cohorts of 100\u2013400 mg of SAHA daily. Secondary objectives included preliminary clinical activity, NK and Treg recovery, response to Prevnar vaccination at cycles 1/3/5, and quality of life data (CES-D, BFI, and FACT-G). Patients at high risk for relapse post HSCT were eligible including DLBCL (induction failure, stage III/IV at relapse, age&gt;60, or elevated LDH at relapse), FL (transformed or 2+ prior regimens), HL (primary refractory or PET positive after salvage), MCL, or T-cell NHL.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Results:</jats:title>\n                  <jats:p>Twenty-three patients (ages 26\u201375, median 55 y.o.) were enrolled \u2013 3 patients at 100 mg, 6 patients at 200 mg, 5 patients at 300 mg, and 9 patients at the 400 mg dose level. Six patients had Hodgkin lymphoma, 6 had MCL, 4 had T-cell NHL, 6 had DLBCL, and 1 had follicular lymphoma.</jats:p>\n                  <jats:p>Of all toxicities (Table 1) potentially related to Vorinostat, fatigue (9.0% of all AE's) and myelosuppression (8.2% platelets, 7.5% ANC, 7.5% Hb) were the most common, followed by diarrhea (6%) and nausea (5.2%). There were three grade 4 and two grade 2 neutropenias, one grade 3 and three grade 2 anemias, and one grade 3 and six grade 2 thrombocytopenias. At dose level 200 mg Vorinostat, patient #6 suffered grade 3 anorexia, the first dose-limiting toxicity (DLT #1), and patient #23 suffered fatigue and anorexia at 400 mg (DLT #2). One patient remains on treatment. A median of 5.5 cycles of treatment were delivered, with a median of 11 cycles for those patients that did not progress. For those that stopped treatment, reasons included toxicities (8 patients), second primary malignancy (1 patient), and infection (1 patient).</jats:p>\n                  <jats:p>Of the 24 patients enrolled and after a median follow-up of 18 months (range 7\u201354 months), the median PFS has not been reached. Sixteen patients were in a CR post-transplant. Of these patients, 6 patients progressed at 4\u201314 months post-transplant with diagnoses of peripheral T-cell lymphoma, T-cell anaplastic large cell, and DLBCL. Of the 7 patients in a PR post-transplant, none has progressed.</jats:p>\n                  <jats:p>Preliminary analysis of Prevnar responses in the first 10 patients enrolled showed no detectable responses for antigens 14, 18c, and 23F. This is different than the 30 myeloma patients post melphalan transplant who received the same Prevnar vaccination schedule (submitted for this meeting) where numerous patients showed antigen responses, suggesting Vorinostat suppresses the adaptive humoral immune response in this patient population. Peripheral blood flow cytometry analysis is ongoing.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions:</jats:title>\n                  <jats:p>Vorinostat was well tolerated in this post autologous transplant population, and we were able to safely dose escalate to 400 mg daily. Fatigue and myelosuppression were the most common toxicities. Complete quality of life, Prevnar responses, and flow cytometric are forthcoming. Deacetylase inhibition post autograft may have clinical efficacy despite suppressing the adaptive immune system.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Disclosures:</jats:title>\n                  <jats:p>No relevant conflicts of interest to declare.</jats:p>\n               </jats:sec>", "DOI": "10.1182/blood.v120.21.2004.2004", "type": "journal-article", "created": {"date-parts": [[2019, 10, 9]], "date-time": "2019-10-09T22:56:37Z", "timestamp": 1570661797000}, "page": "2004-2004", "update-policy": "http://dx.doi.org/10.1182/blood.2019cm0000", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Post Autologous Transplant Vorinostat (SAHA) in High Risk Lymphoma: Phase 1 Study of Vorinostat Maintenance"], "prefix": "10.1182", "volume": "120", "author": [{"given": "Craig C.", "family": "Hofmeister", "sequence": "first", "affiliation": [{"name": "Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH, USA,"}]}, {"given": "Mindy A", "family": "Bowers", "sequence": "additional", "affiliation": [{"name": "Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA,"}]}, {"given": "Robert A.", "family": "Baiocchi", "sequence": "additional", "affiliation": [{"name": "Hematology, The Ohio State University-James Cancer Center, Columbus, OH, USA,"}]}, {"given": "Gerard", "family": "Lozanski", "sequence": "additional", "affiliation": [{"name": "Pathology, The Ohio State University, Columbus, OH, USA,"}]}, {"given": "Kristina", "family": "Humphries", "sequence": "additional", "affiliation": [{"name": "Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA,"}]}, {"given": "Kristie A.", "family": "Blum", "sequence": "additional", "affiliation": [{"name": "Internal Medicine, The Ohio State University, Columbus, OH, USA"}]}, {"given": "Pierluigi", "family": "Porcu", "sequence": "additional", "affiliation": [{"name": "Internal Medicine, The Ohio State University, Columbus, OH, USA"}]}, {"given": "Sam", "family": "Penza", "sequence": "additional", "affiliation": [{"name": "Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH, USA,"}]}, {"given": "Carli N", "family": "Greenfield", "sequence": "additional", "affiliation": [{"name": "Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA,"}]}, {"given": "Megan", "family": "Sell", "sequence": "additional", "affiliation": [{"name": "Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA,"}]}, {"given": "Christian Tyler", "family": "Earl", "sequence": "additional", "affiliation": [{"name": "Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA,"}]}, {"given": "Joseph", "family": "Zitesman", "sequence": "additional", "affiliation": [{"name": "Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA,"}]}, {"given": "Carl", "family": "Quinion", "sequence": "additional", "affiliation": [{"name": "Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA,"}]}, {"given": "Mark E", "family": "Lustberg", "sequence": "additional", "affiliation": [{"name": "Internal Medicine, The Ohio State University, Columbus, OH, USA"}]}, {"given": "Leslie A", "family": "Andritsos", "sequence": "additional", "affiliation": [{"name": "Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH, USA,"}]}, {"given": "Steven M.", "family": "Devine", "sequence": "additional", "affiliation": [{"name": "Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH, USA,"}]}], "member": "234", "container-title": ["Blood"], "language": "en", "link": [{"URL": "https://ashpublications.org/blood/article/120/21/2004/85630/Post-Autologous-Transplant-Vorinostat-SAHA-in-High", "content-type": "application/pdf", "content-version": "vor", "intended-application": "syndication"}, {"URL": "https://ashpublications.org/blood/article/120/21/2004/85630/Post-Autologous-Transplant-Vorinostat-SAHA-in-High", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T03:41:14Z", "timestamp": 1574134874000}, "score": 12.333159, "issued": {"date-parts": [[2012, 11, 16]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2012, 11, 16]]}, "issue": "21"}, "URL": "http://dx.doi.org/10.1182/blood.v120.21.2004.2004", "ISSN": ["0006-4971", "1528-0020"], "issn-type": [{"value": "0006-4971", "type": "print"}, {"value": "1528-0020", "type": "electronic"}], "subject": ["Immunology", "Cell Biology", "Biochemistry", "Hematology"]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T10:59:05Z", "timestamp": 1574506745844}, "reference-count": 0, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2009, 2, 1]], "date-time": "2009-02-01T00:00:00Z", "timestamp": 1233446400000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Clinical Lymphoma and Myeloma"], "published-print": {"date-parts": [[2009, 2]]}, "DOI": "10.1016/s1557-9190(11)70694-1", "type": "journal-article", "created": {"date-parts": [[2012, 9, 27]], "date-time": "2012-09-27T23:28:58Z", "timestamp": 1348788538000}, "page": "S117-S118", "source": "Crossref", "is-referenced-by-count": 2, "title": ["B257 Vorinostat in Combination with Other Anti-MM Agents"], "prefix": "10.1016", "volume": "9", "author": [{"given": "C", "family": "Mitsiades", "sequence": "first", "affiliation": []}, {"given": "PG", "family": "Richardson", "sequence": "additional", "affiliation": []}, {"given": "S", "family": "Grant", "sequence": "additional", "affiliation": []}, {"given": "X-Y", "family": "Pei", "sequence": "additional", "affiliation": []}, {"given": "JR", "family": "Berenson", "sequence": "additional", "affiliation": []}, {"given": "V", "family": "Richon", "sequence": "additional", "affiliation": []}, {"given": "J", "family": "Garcia-Vargas", "sequence": "additional", "affiliation": []}, {"given": "S", "family": "Rizvi", "sequence": "additional", "affiliation": []}, {"given": "KC", "family": "Anderson", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Clinical Lymphoma and Myeloma"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1557919011706941?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1557919011706941?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 11, 20]], "date-time": "2018-11-20T13:24:43Z", "timestamp": 1542720283000}, "score": 12.315613, "issued": {"date-parts": [[2009, 2]]}, "references-count": 0, "alternative-id": ["S1557919011706941"], "URL": "http://dx.doi.org/10.1016/s1557-9190(11)70694-1", "ISSN": ["1557-9190"], "issn-type": [{"value": "1557-9190", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T18:12:32Z", "timestamp": 1574273552614}, "reference-count": 0, "publisher": "American Association for Cancer Research (AACR)", "issue": "2", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Molecular Cancer Therapeutics"], "DOI": "10.1158/1535-7163.mct-06-0562", "type": "journal-article", "created": {"date-parts": [[2007, 2, 16]], "date-time": "2007-02-16T18:31:14Z", "timestamp": 1171650674000}, "page": "692-702", "source": "Crossref", "is-referenced-by-count": 42, "title": ["Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions"], "prefix": "10.1158", "volume": "6", "author": [{"given": "R. R.", "family": "Rosato", "sequence": "first", "affiliation": []}, {"given": "J. A.", "family": "Almenara", "sequence": "additional", "affiliation": []}, {"given": "S. S.", "family": "Kolla", "sequence": "additional", "affiliation": []}, {"given": "S. C.", "family": "Maggio", "sequence": "additional", "affiliation": []}, {"given": "S.", "family": "Coe", "sequence": "additional", "affiliation": []}, {"given": "M. S.", "family": "Gimenez", "sequence": "additional", "affiliation": []}, {"given": "P.", "family": "Dent", "sequence": "additional", "affiliation": []}, {"given": "S.", "family": "Grant", "sequence": "additional", "affiliation": []}], "member": "1086", "published-online": {"date-parts": [[2007, 2, 1]]}, "container-title": ["Molecular Cancer Therapeutics"], "language": "en", "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/1535-7163.MCT-06-0562", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2016, 12, 23]], "date-time": "2016-12-23T07:59:48Z", "timestamp": 1482479988000}, "score": 11.5415325, "issued": {"date-parts": [[2007, 2, 1]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2007, 2, 1]]}, "issue": "2"}, "URL": "http://dx.doi.org/10.1158/1535-7163.mct-06-0562", "ISSN": ["1535-7163", "1538-8514"], "issn-type": [{"value": "1535-7163", "type": "print"}, {"value": "1538-8514", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T11:55:21Z", "timestamp": 1574337321644}, "reference-count": 0, "publisher": "American Association for Cancer Research (AACR)", "issue": "12", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Molecular Cancer Therapeutics"], "DOI": "10.1158/1535-7163.mct-07-0561", "type": "journal-article", "created": {"date-parts": [[2007, 12, 8]], "date-time": "2007-12-08T01:44:44Z", "timestamp": 1197078284000}, "page": "3101-3112", "source": "Crossref", "is-referenced-by-count": 21, "title": ["Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells"], "prefix": "10.1158", "volume": "6", "author": [{"given": "C.", "family": "Mitchell", "sequence": "first", "affiliation": []}, {"given": "M. A.", "family": "Park", "sequence": "additional", "affiliation": []}, {"given": "G.", "family": "Zhang", "sequence": "additional", "affiliation": []}, {"given": "A.", "family": "Yacoub", "sequence": "additional", "affiliation": []}, {"given": "D. T.", "family": "Curiel", "sequence": "additional", "affiliation": []}, {"given": "P. B.", "family": "Fisher", "sequence": "additional", "affiliation": []}, {"given": "J. D.", "family": "Roberts", "sequence": "additional", "affiliation": []}, {"given": "S.", "family": "Grant", "sequence": "additional", "affiliation": []}, {"given": "P.", "family": "Dent", "sequence": "additional", "affiliation": []}], "member": "1086", "published-online": {"date-parts": [[2007, 12, 7]]}, "container-title": ["Molecular Cancer Therapeutics"], "language": "en", "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/1535-7163.MCT-07-0561", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2016, 12, 23]], "date-time": "2016-12-23T08:15:39Z", "timestamp": 1482480939000}, "score": 11.5415325, "issued": {"date-parts": [[2007, 12, 7]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2007, 12, 7]]}, "issue": "12"}, "URL": "http://dx.doi.org/10.1158/1535-7163.mct-07-0561", "ISSN": ["1535-7163", "1538-8514"], "issn-type": [{"value": "1535-7163", "type": "print"}, {"value": "1538-8514", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 12, 19]], "date-time": "2019-12-19T23:59:07Z", "timestamp": 1576799947823}, "reference-count": 0, "publisher": "American Society of Clinical Oncology (ASCO)", "issue": "15_suppl", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["JCO"], "published-print": {"date-parts": [[2008, 5, 20]]}, "DOI": "10.1200/jco.2008.26.15_suppl.8548", "type": "journal-article", "created": {"date-parts": [[2017, 2, 24]], "date-time": "2017-02-24T07:33:44Z", "timestamp": 1487921624000}, "page": "8548-8548", "source": "Crossref", "is-referenced-by-count": 3, "title": ["Phase I trial of vorinostat plus bortezomib (bort) in relapsed/refractory multiple myeloma (mm) patients (pts)"], "prefix": "10.1200", "volume": "26", "author": [{"given": "A. Z.", "family": "Badros", "sequence": "first", "affiliation": []}, {"given": "S.", "family": "Philip", "sequence": "additional", "affiliation": []}, {"given": "R.", "family": "Niesvizk", "sequence": "additional", "affiliation": []}, {"given": "O.", "family": "Goloubeva", "sequence": "additional", "affiliation": []}, {"given": "C.", "family": "Harris", "sequence": "additional", "affiliation": []}, {"given": "J.", "family": "Zweibel", "sequence": "additional", "affiliation": []}, {"given": "J. J.", "family": "Wright", "sequence": "additional", "affiliation": []}, {"given": "A.", "family": "Burger", "sequence": "additional", "affiliation": []}, {"given": "M. R.", "family": "Baer", "sequence": "additional", "affiliation": []}, {"given": "M. J.", "family": "Egorin", "sequence": "additional", "affiliation": []}, {"given": "S.", "family": "Grant", "sequence": "additional", "affiliation": []}], "member": "233", "container-title": ["Journal of Clinical Oncology"], "language": "en", "link": [{"URL": "http://ascopubs.org/doi/pdfdirect/10.1200/jco.2008.26.15_suppl.8548", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T22:10:40Z", "timestamp": 1574892640000}, "score": 11.5415325, "issued": {"date-parts": [[2008, 5, 20]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2008, 5, 20]]}, "issue": "15_suppl"}, "alternative-id": ["10.1200/jco.2008.26.15_suppl.8548"], "URL": "http://dx.doi.org/10.1200/jco.2008.26.15_suppl.8548", "ISSN": ["0732-183X", "1527-7755"], "issn-type": [{"value": "0732-183X", "type": "print"}, {"value": "1527-7755", "type": "electronic"}], "subject": ["Cancer Research", "Oncology"]}, {"indexed": {"date-parts": [[2019, 12, 20]], "date-time": "2019-12-20T00:00:12Z", "timestamp": 1576800012484}, "reference-count": 0, "publisher": "American Society of Clinical Oncology (ASCO)", "issue": "15_suppl", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["JCO"], "published-print": {"date-parts": [[2010, 5, 20]]}, "DOI": "10.1200/jco.2010.28.15_suppl.e13511", "type": "journal-article", "created": {"date-parts": [[2017, 2, 24]], "date-time": "2017-02-24T02:41:10Z", "timestamp": 1487904070000}, "page": "e13511-e13511", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Phase I trial of pulse-dose vorinostat with flavopiridol in solid tumors."], "prefix": "10.1200", "volume": "28", "author": [{"given": "M. A.", "family": "Dickson", "sequence": "first", "affiliation": []}, {"given": "D. E.", "family": "Rathkopf", "sequence": "additional", "affiliation": []}, {"given": "S.", "family": "Grant", "sequence": "additional", "affiliation": []}, {"given": "J. D.", "family": "Roberts", "sequence": "additional", "affiliation": []}, {"given": "J. M.", "family": "Reid", "sequence": "additional", "affiliation": []}, {"given": "M. M.", "family": "Ames", "sequence": "additional", "affiliation": []}, {"given": "R. M.", "family": "McGovern", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "Gonen", "sequence": "additional", "affiliation": []}, {"given": "H. J.", "family": "Dials", "sequence": "additional", "affiliation": []}, {"given": "G. K.", "family": "Schwartz", "sequence": "additional", "affiliation": []}], "member": "233", "container-title": ["Journal of Clinical Oncology"], "language": "en", "link": [{"URL": "http://ascopubs.org/doi/pdfdirect/10.1200/jco.2010.28.15_suppl.e13511", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T21:55:59Z", "timestamp": 1574891759000}, "score": 11.5415325, "issued": {"date-parts": [[2010, 5, 20]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2010, 5, 20]]}, "issue": "15_suppl"}, "alternative-id": ["10.1200/jco.2010.28.15_suppl.e13511"], "URL": "http://dx.doi.org/10.1200/jco.2010.28.15_suppl.e13511", "ISSN": ["0732-183X", "1527-7755"], "issn-type": [{"value": "0732-183X", "type": "print"}, {"value": "1527-7755", "type": "electronic"}], "subject": ["Cancer Research", "Oncology"]}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T14:14:45Z", "timestamp": 1574432085006}, "reference-count": 0, "publisher": "Informa UK Limited", "issue": "10", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Cancer Biology & Therapy"], "published-print": {"date-parts": [[2008, 10]]}, "DOI": "10.4161/cbt.7.10.6623", "type": "journal-article", "created": {"date-parts": [[2010, 5, 26]], "date-time": "2010-05-26T19:16:43Z", "timestamp": 1274901403000}, "page": "1648-1662", "source": "Crossref", "is-referenced-by-count": 102, "title": ["Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation"], "prefix": "10.1080", "volume": "7", "author": [{"given": "Margaret A.", "family": "Park", "sequence": "first", "affiliation": []}, {"given": "Guo", "family": "Zhang", "sequence": "additional", "affiliation": []}, {"given": "Aditi Pandya", "family": "Martin", "sequence": "additional", "affiliation": []}, {"given": "Hossein", "family": "Hamed", "sequence": "additional", "affiliation": []}, {"given": "Clint", "family": "Mitchell", "sequence": "additional", "affiliation": []}, {"given": "Philip B.", "family": "Hylemon", "sequence": "additional", "affiliation": []}, {"given": "Martin", "family": "Graf", "sequence": "additional", "affiliation": []}, {"given": "Mohamed", "family": "Rahmani", "sequence": "additional", "affiliation": []}, {"given": "Kevin", "family": "Ryan", "sequence": "additional", "affiliation": []}, {"given": "Xiang", "family": "Liu", "sequence": "additional", "affiliation": []}, {"given": "Sarah", "family": "Spiegel", "sequence": "additional", "affiliation": []}, {"given": "James", "family": "Norris", "sequence": "additional", "affiliation": []}, {"given": "Paul B.", "family": "Fisher", "sequence": "additional", "affiliation": []}, {"given": "Steven", "family": "Grant", "sequence": "additional", "affiliation": []}, {"given": "Paul", "family": "Dent", "sequence": "additional", "affiliation": []}], "member": "301", "published-online": {"date-parts": [[2014, 10, 27]]}, "container-title": ["Cancer Biology & Therapy"], "language": "en", "link": [{"URL": "http://www.tandfonline.com/doi/pdf/10.4161/cbt.7.10.6623", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2016, 12, 12]], "date-time": "2016-12-12T09:52:24Z", "timestamp": 1481536344000}, "score": 11.471964, "issued": {"date-parts": [[2008, 10]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2014, 10, 27]]}, "published-print": {"date-parts": [[2008, 10]]}, "issue": "10"}, "alternative-id": ["10.4161/cbt.7.10.6623"], "URL": "http://dx.doi.org/10.4161/cbt.7.10.6623", "ISSN": ["1538-4047", "1555-8576"], "issn-type": [{"value": "1538-4047", "type": "print"}, {"value": "1555-8576", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T13:20:22Z", "timestamp": 1574428822896}, "reference-count": 39, "publisher": "Springer Science and Business Media LLC", "issue": "5", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2010, 5, 12]], "date-time": "2010-05-12T00:00:00Z", "timestamp": 1273622400000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Invest New Drugs"], "published-print": {"date-parts": [[2011, 10]]}, "DOI": "10.1007/s10637-010-9447-x", "type": "journal-article", "created": {"date-parts": [[2010, 5, 11]], "date-time": "2010-05-11T02:17:50Z", "timestamp": 1273544270000}, "page": "1004-1012", "source": "Crossref", "is-referenced-by-count": 20, "title": ["A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors"], "prefix": "10.1007", "volume": "29", "author": [{"given": "Mark Andrew", "family": "Dickson", "sequence": "first", "affiliation": []}, {"given": "Dana E.", "family": "Rathkopf", "sequence": "additional", "affiliation": []}, {"given": "Richard D.", "family": "Carvajal", "sequence": "additional", "affiliation": []}, {"given": "Steven", "family": "Grant", "sequence": "additional", "affiliation": []}, {"given": "John D.", "family": "Roberts", "sequence": "additional", "affiliation": []}, {"given": "Joel M.", "family": "Reid", "sequence": "additional", "affiliation": []}, {"given": "Matthew M.", "family": "Ames", "sequence": "additional", "affiliation": []}, {"given": "Renee M.", "family": "McGovern", "sequence": "additional", "affiliation": []}, {"given": "Robert A.", "family": "Lefkowitz", "sequence": "additional", "affiliation": []}, {"given": "Mithat", "family": "Gonen", "sequence": "additional", "affiliation": []}, {"given": "Lauren M.", "family": "Cane", "sequence": "additional", "affiliation": []}, {"given": "Heather J.", "family": "Dials", "sequence": "additional", "affiliation": []}, {"given": "Gary K.", "family": "Schwartz", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2010, 5, 12]]}, "reference": [{"key": "9447_CR1", "doi-asserted-by": "crossref", "first-page": "349", "DOI": "10.1038/38664", "volume": "389", "author": "M Grunstein", "year": "1997", "unstructured": "Grunstein M (1997) Histone acetylation in chromatin structure and transcription. Nature 389:349\u2013352", "journal-title": "Nature"}, {"key": "9447_CR2", "doi-asserted-by": "crossref", "first-page": "287", "DOI": "10.1038/nrd772", "volume": "1", "author": "RW Johnstone", "year": "2002", "unstructured": "Johnstone RW (2002) Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1:287\u2013299", "journal-title": "Nat Rev Drug Discov"}, {"key": "9447_CR3", "doi-asserted-by": "crossref", "first-page": "194", "DOI": "10.1038/35106079", "volume": "1", "author": "P Marks", "year": "2001", "unstructured": "Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1:194\u2013202", "journal-title": "Nat Rev Cancer"}, {"key": "9447_CR4", "doi-asserted-by": "crossref", "first-page": "415", "DOI": "10.1038/nrg962", "volume": "3", "author": "PA Jones", "year": "2002", "unstructured": "Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415\u2013428", "journal-title": "Nat Rev Genet"}, {"key": "9447_CR5", "doi-asserted-by": "crossref", "first-page": "2343", "DOI": "10.2174/0929867033456657", "volume": "10", "author": "J Arts", "year": "2003", "unstructured": "Arts J, de Schepper S, Van Emelen K (2003) Histone deacetylase inhibitors: from chromatin remodeling to experimental cancer therapeutics. Curr Med Chem 10:2343\u20132350", "journal-title": "Curr Med Chem"}, {"key": "9447_CR6", "doi-asserted-by": "crossref", "first-page": "188", "DOI": "10.1038/43710", "volume": "401", "author": "MS Finnin", "year": "1999", "unstructured": "Finnin MS, Donigian JR, Cohen A et al (1999) Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401:188\u2013193", "journal-title": "Nature"}, {"key": "9447_CR7", "doi-asserted-by": "crossref", "first-page": "18", "DOI": "10.1158/1078-0432.CCR-06-0914", "volume": "13", "author": "NB Arnold", "year": "2007", "unstructured": "Arnold NB, Arkus N, Gunn J, Korc M (2007) The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer. Clin Cancer Res 13:18\u201326", "journal-title": "Clin Cancer Res"}, {"key": "9447_CR8", "doi-asserted-by": "crossref", "first-page": "1901", "DOI": "10.1016/j.bcp.2007.03.009", "volume": "73", "author": "J Shen", "year": "2007", "unstructured": "Shen J, Huang C, Jiang L et al (2007) Enhancement of cisplatin induced apoptosis by suberoylanilide hydroxamic acid in human oral squamous cell carcinoma cell lines. Biochem Pharmacol 73:1901\u20131909", "journal-title": "Biochem Pharmacol"}, {"key": "9447_CR9", "doi-asserted-by": "crossref", "first-page": "3923", "DOI": "10.1200/JCO.2005.14.167", "volume": "23", "author": "WK Kelly", "year": "2005", "unstructured": "Kelly WK, O\u2019Connor OA, Krug LM et al (2005) Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23:3923\u20133931", "journal-title": "J Clin Oncol"}, {"key": "9447_CR10", "unstructured": "Cheema HS, Motwani MV, Schwartz GK (2004) Suberoylanilide Hydroxamic Acid (SAHA), a histone deacetylase (HDAC) inhibitor, induces a unique mitotic effect and potentiates flavopiridol (F) induced apoptosis [abstract]. Proc Am Assoc Cancer Res 45: Abstract #2443"}, {"key": "9447_CR11", "doi-asserted-by": "crossref", "first-page": "2081", "DOI": "10.1016/S0040-4020(01)90352-7", "volume": "44", "author": "RG Naik", "year": "1988", "unstructured": "Naik RG, Kattige SL, Bhat SV, Alreja B, de Souza NJ, Rupp RH (1988) An antiinflammatory cum immunomodulatory piperidinylbenzopyranone from dysoxylum binectariferum: isolation, structure and total synthesis. Tetrahedron 44:2081\u20132086", "journal-title": "Tetrahedron"}, {"key": "9447_CR12", "first-page": "2973", "volume": "56", "author": "BA Carlson", "year": "1996", "unstructured": "Carlson BA, Dubay MM, Sausville EA, Brizuela L, Worland PJ (1996) Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 56:2973\u20132978", "journal-title": "Cancer Res"}, {"key": "9447_CR13", "doi-asserted-by": "crossref", "first-page": "589", "DOI": "10.1006/bbrc.1994.1742", "volume": "201", "author": "MD Losiewicz", "year": "1994", "unstructured": "Losiewicz MD, Carlson BA, Kaur G, Sausville EA, Worland PJ (1994) Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem Biophys Res Commun 201:589\u2013595", "journal-title": "Biochem Biophys Res Commun"}, {"key": "9447_CR14", "doi-asserted-by": "crossref", "first-page": "1770", "DOI": "10.1200/JCO.2005.03.7689", "volume": "24", "author": "GI Shapiro", "year": "2006", "unstructured": "Shapiro GI (2006) Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 24:1770\u20131783", "journal-title": "J Clin Oncol"}, {"key": "9447_CR15", "doi-asserted-by": "crossref", "first-page": "1331", "DOI": "10.1038/sj.leu.2402535", "volume": "16", "author": "J Almenara", "year": "2002", "unstructured": "Almenara J, Rosato R, Grant S (2002) Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). Leukemia 16:1331\u20131343", "journal-title": "Leukemia"}, {"key": "9447_CR16", "doi-asserted-by": "crossref", "first-page": "3101", "DOI": "10.1158/1535-7163.MCT-07-0561", "volume": "6", "author": "C Mitchell", "year": "2007", "unstructured": "Mitchell C, Park MA, Zhang G et al (2007) Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells. Mol Cancer Ther 6:3101\u20133112", "journal-title": "Mol Cancer Ther"}, {"key": "9447_CR17", "first-page": "288", "volume": "69", "author": "G Dasmahapatra", "year": "2006", "unstructured": "Dasmahapatra G, Almenara JA, Grant S (2006) Flavopiridol and histone deacetylase inhibitors promote mitochondrial injury and cell death in human leukemia cells that overexpress Bcl-2. Mol Pharmacol 69:288\u2013298", "journal-title": "Mol Pharmacol"}, {"key": "9447_CR18", "doi-asserted-by": "crossref", "first-page": "956", "DOI": "10.1124/mol.104.002014", "volume": "66", "author": "N Gao", "year": "2004", "unstructured": "Gao N, Dai Y, Rahmani M, Dent P, Grant S (2004) Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol. Mol Pharmacol 66:956\u2013963", "journal-title": "Mol Pharmacol"}, {"key": "9447_CR19", "doi-asserted-by": "crossref", "first-page": "5429", "DOI": "10.1128/MCB.25.13.5429-5444.2005", "volume": "25", "author": "Y Dai", "year": "2005", "unstructured": "Dai Y, Rahmani M, Dent P, Grant S (2005) Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation. Mol Cell Biol 25:5429\u20135444", "journal-title": "Mol Cell Biol"}, {"key": "9447_CR20", "doi-asserted-by": "crossref", "first-page": "31", "DOI": "10.1182/blood-2006-06-025999", "volume": "109", "author": "M Duvic", "year": "2007", "unstructured": "Duvic M, Talpur R, Ni X et al (2007) Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109:31\u201339", "journal-title": "Blood"}, {"key": "9447_CR21", "doi-asserted-by": "crossref", "first-page": "160", "DOI": "10.3816/CLC.2008.n.024", "volume": "9", "author": "S George", "year": "2008", "unstructured": "George S, Kasimis BS, Cogswell J et al (2008) Phase I study of flavopiridol in combination with Paclitaxel and Carboplatin in patients with non-small-cell lung cancer. Clin Lung Cancer 9:160\u2013165", "journal-title": "Clin Lung Cancer"}, {"key": "9447_CR22", "doi-asserted-by": "crossref", "first-page": "5841", "DOI": "10.1158/1078-0432.CCR-07-1218", "volume": "13", "author": "MN Fornier", "year": "2007", "unstructured": "Fornier MN, Rathkopf D, Shah M et al (2007) Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors. Clin Cancer Res 13:5841\u20135846", "journal-title": "Clin Cancer Res"}, {"key": "9447_CR23", "doi-asserted-by": "crossref", "first-page": "2157", "DOI": "10.1200/JCO.2002.08.080", "volume": "20", "author": "GK Schwartz", "year": "2002", "unstructured": "Schwartz GK, O\u2019Reilly E, Ilson D et al (2002) Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J Clin Oncol 20:2157\u20132170", "journal-title": "J Clin Oncol"}, {"key": "9447_CR24", "doi-asserted-by": "crossref", "first-page": "176", "DOI": "10.1016/S1053-4296(03)00031-6", "volume": "13", "author": "A Trotti", "year": "2003", "unstructured": "Trotti A, Colevas AD, Setser A et al (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176\u2013181", "journal-title": "Semin Radiat Oncol"}, {"key": "9447_CR25", "doi-asserted-by": "crossref", "first-page": "205", "DOI": "10.1093/jnci/92.3.205", "volume": "92", "author": "P Therasse", "year": "2000", "unstructured": "Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216", "journal-title": "J Natl Cancer Inst"}, {"key": "9447_CR26", "doi-asserted-by": "crossref", "first-page": "108", "DOI": "10.1016/j.jchromb.2006.04.044", "volume": "840", "author": "RA Parise", "year": "2006", "unstructured": "Parise RA, Holleran JL, Beumer JH, Ramalingam S, Egorin MJ (2006) A liquid chromatography-electrospray ionization tandem mass spectrometric assay for quantitation of the histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamicacid, SAHA), and its metabolites in human serum. J Chromatogr B Analyt Technol Biomed Life Sci 840:108\u2013115", "journal-title": "J Chromatogr B Analyt Technol Biomed Life Sci"}, {"key": "9447_CR27", "doi-asserted-by": "crossref", "first-page": "399", "DOI": "10.1182/blood-2006-05-020735", "volume": "109", "author": "JC Byrd", "year": "2007", "unstructured": "Byrd JC, Lin TS, Dalton JT et al (2007) Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 109:399\u2013404", "journal-title": "Blood"}, {"key": "9447_CR28", "doi-asserted-by": "crossref", "first-page": "131", "DOI": "10.1016/j.cct.2004.12.007", "volume": "26", "author": "M Gonen", "year": "2005", "unstructured": "Gonen M (2005) A Bayesian evaluation of enrolling additional patients at the maximum tolerated dose in Phase I trials. Contemp Clin Trials 26:131\u2013140", "journal-title": "Contemp Clin Trials"}, {"key": "9447_CR29", "doi-asserted-by": "crossref", "first-page": "3836", "DOI": "10.1158/1078-0432.CCR-04-2651", "volume": "11", "author": "MA Shah", "year": "2005", "unstructured": "Shah MA, Kortmansky J, Motwani M et al (2005) A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. Clin Cancer Res 11:3836\u20133845", "journal-title": "Clin Cancer Res"}, {"key": "9447_CR30", "doi-asserted-by": "crossref", "first-page": "6012", "DOI": "10.1200/JCO.2009.22.6944", "volume": "27", "author": "TS Lin", "year": "2009", "unstructured": "Lin TS, Ruppert AS, Johnson AJ et al (2009) Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol 27:6012\u20136018", "journal-title": "J Clin Oncol"}, {"key": "9447_CR31", "unstructured": "Fakih MG, Egorin MJ, Fetterly G et al (2010) A phase I study of QD and BID vorinostat \u00d7 3\u00a0days and sFULV2 in refractory colorectal cancer and other solid tumors. ASCO Gastrointestinal Cancers Symposium. Abstract 334"}, {"key": "9447_CR32", "first-page": "3578", "volume": "9", "author": "WK Kelly", "year": "2003", "unstructured": "Kelly WK, Richon VM, O\u2019Connor O et al (2003) Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 9:3578\u20133588", "journal-title": "Clin Cancer Res"}, {"key": "9447_CR33", "doi-asserted-by": "crossref", "first-page": "3605", "DOI": "10.1158/1078-0432.CCR-07-0162", "volume": "13", "author": "SS Ramalingam", "year": "2007", "unstructured": "Ramalingam SS, Parise RA, Ramanathan RK et al (2007) Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res 13:3605\u20133610", "journal-title": "Clin Cancer Res"}, {"key": "9447_CR34", "doi-asserted-by": "crossref", "first-page": "3189", "DOI": "10.1158/1078-0432.CCR-08-2999", "volume": "15", "author": "MG Fakih", "year": "2009", "unstructured": "Fakih MG, Pendyala L, Fetterly G et al (2009) A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer. Clin Cancer Res 15:3189\u20133195", "journal-title": "Clin Cancer Res"}, {"key": "9447_CR35", "doi-asserted-by": "crossref", "first-page": "7039", "DOI": "10.1158/1078-0432.CCR-06-1802", "volume": "12", "author": "EH Rubin", "year": "2006", "unstructured": "Rubin EH, Agrawal NG, Friedman EJ et al (2006) A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer. Clin Cancer Res 12:7039\u20137045", "journal-title": "Clin Cancer Res"}, {"key": "9447_CR36", "doi-asserted-by": "crossref", "first-page": "1060", "DOI": "10.1182/blood-2007-06-098061", "volume": "111", "author": "G Garcia-Manero", "year": "2008", "unstructured": "Garcia-Manero G, Yang H, Bueso-Ramos C et al (2008) Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 111:1060\u20131066", "journal-title": "Blood"}, {"key": "9447_CR37", "doi-asserted-by": "crossref", "first-page": "502", "DOI": "10.1080/10428190701817258", "volume": "49", "author": "P Richardson", "year": "2008", "unstructured": "Richardson P, Mitsiades C, Colson K et al (2008) Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma 49:502\u2013507", "journal-title": "Leuk Lymphoma"}, {"key": "9447_CR38", "doi-asserted-by": "crossref", "first-page": "964", "DOI": "10.1093/annonc/mdn031", "volume": "19", "author": "M Crump", "year": "2008", "unstructured": "Crump M, Coiffier B, Jacobsen ED et al (2008) Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol 19:964\u2013969", "journal-title": "Ann Oncol"}, {"key": "9447_CR39", "unstructured": "Grant S, Kolla S, Sirulnik L et al (2008) Phase I trial of vorinostat (SAHA) in combination with alvocidib (Flavopiridol) in patients with relapsed, refractory or (selected) poor prognosis acute leukemia or refractory anemia with excess blasts-2 (RAEB-2). Blood (ASH Annual Meeting Abstracts) 112: Abstract #2986"}], "container-title": ["Investigational New Drugs"], "language": "en", "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/s10637-010-9447-x.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/article/10.1007/s10637-010-9447-x/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/content/pdf/10.1007/s10637-010-9447-x", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 30]], "date-time": "2019-05-30T20:01:31Z", "timestamp": 1559246491000}, "score": 11.471964, "issued": {"date-parts": [[2010, 5, 12]]}, "references-count": 39, "journal-issue": {"published-print": {"date-parts": [[2011, 10]]}, "issue": "5"}, "alternative-id": ["9447"], "URL": "http://dx.doi.org/10.1007/s10637-010-9447-x", "relation": {"cites": []}, "ISSN": ["0167-6997", "1573-0646"], "issn-type": [{"value": "0167-6997", "type": "print"}, {"value": "1573-0646", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T08:50:05Z", "timestamp": 1574412605116}, "reference-count": 37, "publisher": "Oxford University Press (OUP)", "issue": "1", "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2012, 1]]}, "DOI": "10.1093/neuonc/nor187", "type": "journal-article", "created": {"date-parts": [[2011, 10, 26]], "date-time": "2011-10-26T00:54:31Z", "timestamp": 1319590471000}, "page": "93-100", "source": "Crossref", "is-referenced-by-count": 34, "title": ["Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma"], "prefix": "10.1093", "volume": "14", "author": [{"given": "Prakash", "family": "Chinnaiyan", "sequence": "first", "affiliation": []}, {"given": "Sajeel", "family": "Chowdhary", "sequence": "additional", "affiliation": []}, {"given": "Lisa", "family": "Potthast", "sequence": "additional", "affiliation": []}, {"given": "Antony", "family": "Prabhu", "sequence": "additional", "affiliation": []}, {"given": "Ya-Yu", "family": "Tsai", "sequence": "additional", "affiliation": []}, {"given": "Bhaswati", "family": "Sarcar", "sequence": "additional", "affiliation": []}, {"given": "Soumen", "family": "Kahali", "sequence": "additional", "affiliation": []}, {"given": "Steven", "family": "Brem", "sequence": "additional", "affiliation": []}, {"given": "H. Michael", "family": "Yu", "sequence": "additional", "affiliation": []}, {"given": "Amyn", "family": "Rojiani", "sequence": "additional", "affiliation": []}, {"given": "Ryan", "family": "Murtagh", "sequence": "additional", "affiliation": []}, {"given": "Edward", "family": "Pan", "sequence": "additional", "affiliation": []}], "member": "286", "published-online": {"date-parts": [[2011, 10, 25]]}, "reference": [{"issue": "5", "key": "key\n\t\t\t\t20170508184906_NOR187C1", "doi-asserted-by": "crossref", "first-page": "492", "DOI": "10.1056/NEJMra0708126", "article-title": "Malignant gliomas in adults", "volume": "359", "author": "Wen", "year": "2008", "journal-title": "The New England Journal of Medicine"}, {"issue": "10", "key": "key\n\t\t\t\t20170508184906_NOR187C2", "doi-asserted-by": "crossref", "first-page": "987", "DOI": "10.1056/NEJMoa043330", "article-title": "Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma", "volume": "352", "author": "Stupp", "year": "2005", "journal-title": "The New England Journal of Medicine"}, {"issue": "8", "key": "key\n\t\t\t\t20170508184906_NOR187C3", "doi-asserted-by": "crossref", "first-page": "2572", "DOI": "10.1200/JCO.1999.17.8.2572", "article-title": "Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials", "volume": "17", "author": "Wong", "year": "1999", "journal-title": "J Clin Oncol"}, {"issue": "28", "key": "key\n\t\t\t\t20170508184906_NOR187C4", "doi-asserted-by": "crossref", "first-page": "4733", "DOI": "10.1200/JCO.2008.19.8721", "article-title": "Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma", "volume": "27", "author": "Friedman", "year": "2009", "journal-title": "J Clin Oncol"}, {"issue": "30", "key": "key\n\t\t\t\t20170508184906_NOR187C5", "doi-asserted-by": "crossref", "first-page": "4722", "DOI": "10.1200/JCO.2007.12.2440", "article-title": "Bevacizumab plus irinotecan in recurrent glioblastoma multiforme", "volume": "25", "author": "Vredenburgh", "year": "2007", "journal-title": "J Clin Oncol"}, {"issue": "5", "key": "key\n\t\t\t\t20170508184906_NOR187C6", "doi-asserted-by": "crossref", "first-page": "740", "DOI": "10.1200/JCO.2008.16.3055", "article-title": "Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma", "volume": "27", "author": "Kreisl", "year": "2009", "journal-title": "J Clin Oncol"}, {"issue": "2", "key": "key\n\t\t\t\t20170508184906_NOR187C7", "doi-asserted-by": "crossref", "first-page": "149", "DOI": "10.1007/s11060-008-9745-8", "article-title": "An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma", "volume": "92", "author": "Norden", "year": "2009", "journal-title": "Journal of Neuro-oncology"}, {"issue": "11", "key": "key\n\t\t\t\t20170508184906_NOR187C8", "doi-asserted-by": "crossref", "first-page": "610", "DOI": "10.1038/nrneurol.2009.159", "article-title": "Antiangiogenic therapies for high-grade glioma", "volume": "5", "author": "Norden", "year": "2009", "journal-title": "Nat Rev Neurol"}, {"issue": "1", "key": "key\n\t\t\t\t20170508184906_NOR187C9", "doi-asserted-by": "crossref", "first-page": "31", "DOI": "10.1182/blood-2006-06-025999", "article-title": "Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)", "volume": "109", "author": "Duvic", "year": "2007", "journal-title": "Blood"}, {"issue": "12", "key": "key\n\t\t\t\t20170508184906_NOR187C10", "doi-asserted-by": "crossref", "first-page": "2052", "DOI": "10.1200/JCO.2008.19.0694", "article-title": "Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study", "volume": "27", "author": "Galanis", "year": "2009", "journal-title": "J Clin Oncol"}, {"issue": "2", "key": "key\n\t\t\t\t20170508184906_NOR187C11", "doi-asserted-by": "crossref", "first-page": "634", "DOI": "10.1158/1078-0432.CCR-05-1132", "article-title": "Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589", "volume": "12", "author": "Qian", "year": "2006", "journal-title": "Clin Cancer Res"}, {"issue": "18", "key": "key\n\t\t\t\t20170508184906_NOR187C12", "doi-asserted-by": "crossref", "first-page": "6626", "DOI": "10.1158/0008-5472.CAN-04-0540", "article-title": "The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584", "volume": "64", "author": "Qian", "year": "2004", "journal-title": "Cancer Research"}, {"issue": "15", "key": "key\n\t\t\t\t20170508184906_NOR187C13", "doi-asserted-by": "crossref", "first-page": "6957", "DOI": "10.1158/0008-5472.CAN-05-0836", "article-title": "It's about time: scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells", "volume": "65", "author": "Bevins", "year": "2005", "journal-title": "Cancer Research"}, {"issue": "9", "key": "key\n\t\t\t\t20170508184906_NOR187C14", "doi-asserted-by": "crossref", "first-page": "3815", "DOI": "10.1158/0008-5472.CAN-04-2478", "article-title": "Valproic acid alters chromatin structure by regulation of chromatin modulation proteins", "volume": "65", "author": "Marchion", "year": "2005", "journal-title": "Cancer Research"}, {"issue": "12", "key": "key\n\t\t\t\t20170508184906_NOR187C15", "doi-asserted-by": "crossref", "first-page": "1993", "DOI": "10.1158/1535-7163.MCT-05-0194", "article-title": "In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates", "volume": "4", "author": "Marchion", "year": "2005", "journal-title": "Molecular Cancer Therapeutics"}, {"issue": "2", "key": "key\n\t\t\t\t20170508184906_NOR187C16", "doi-asserted-by": "crossref", "first-page": "201", "DOI": "10.1007/s11060-010-0127-7", "article-title": "Vorinostat enhances the cytotoxic effects of the topoisomerase I inhibitor SN38 in glioblastoma cell lines", "volume": "99", "author": "Sarcar", "year": "2010", "journal-title": "Journal of Neuro-oncology"}, {"issue": "1", "key": "key\n\t\t\t\t20170508184906_NOR187C17", "doi-asserted-by": "crossref", "first-page": "69", "DOI": "10.1016/j.ccr.2006.11.020", "article-title": "A perivascular niche for brain tumor stem cells", "volume": "11", "author": "Calabrese", "year": "2007", "journal-title": "Cancer Cell"}, {"issue": "28", "key": "key\n\t\t\t\t20170508184906_NOR187C18", "doi-asserted-by": "crossref", "first-page": "11736", "DOI": "10.1073/pnas.0703145104", "article-title": "Insulin-like growth factor binding protein 2 promotes glioma development and progression", "volume": "104", "author": "Dunlap", "year": "2007", "journal-title": "Proceedings of the National Academy of Sciences of the United States of America"}, {"issue": "13", "key": "key\n\t\t\t\t20170508184906_NOR187C19", "doi-asserted-by": "crossref", "first-page": "5563", "DOI": "10.1073/pnas.0609139104", "article-title": "Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer", "volume": "104", "author": "Mehrian-Shai", "year": "2007", "journal-title": "Proceedings of the National Academy of Sciences of the United States of America"}, {"issue": "39", "key": "key\n\t\t\t\t20170508184906_NOR187C20", "doi-asserted-by": "crossref", "first-page": "16675", "DOI": "10.1073/pnas.0900807106", "article-title": "IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas", "volume": "106", "author": "Moore", "year": "2009", "journal-title": "Proceedings of the National Academy of Sciences of the United States of America"}, {"issue": "6", "key": "key\n\t\t\t\t20170508184906_NOR187C21", "doi-asserted-by": "crossref", "first-page": "1399", "DOI": "10.1158/1055-9965.EPI-09-1213", "article-title": "Grade-specific expression of insulin-like growth factor-binding proteins-2, -3, and -5 in astrocytomas: IGFBP-3 emerges as a strong predictor of survival in patients with newly diagnosed glioblastoma", "volume": "19", "author": "Santosh", "year": "2010", "journal-title": "Cancer Epidemiol Biomarkers Prev"}, {"issue": "9", "key": "key\n\t\t\t\t20170508184906_NOR187C22", "doi-asserted-by": "crossref", "first-page": "3466", "DOI": "10.1073/pnas.0611271104", "article-title": "Identification of IGF2 signaling through phosphoinositide-3-kinase regulatory subunit 3 as a growth-promoting axis in glioblastoma", "volume": "104", "author": "Soroceanu", "year": "2007", "journal-title": "Proceedings of the National Academy of Sciences of the United States of America"}, {"issue": "15", "key": "key\n\t\t\t\t20170508184906_NOR187C23", "first-page": "4315", "article-title": "Insulin-like growth factor binding protein 2 enhances glioblastoma invasion by activating invasion-enhancing genes", "volume": "63", "author": "Wang", "year": "2003", "journal-title": "Cancer Research"}, {"issue": "5", "key": "key\n\t\t\t\t20170508184906_NOR187C24", "doi-asserted-by": "crossref", "first-page": "468", "DOI": "10.1215/15228517-2008-114", "article-title": "Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas", "volume": "11", "author": "Lin", "year": "2009", "journal-title": "Neuro-oncology"}, {"issue": "6", "key": "key\n\t\t\t\t20170508184906_NOR187C25", "doi-asserted-by": "crossref", "first-page": "1409", "DOI": "10.1158/1055-9965.EPI-09-1077", "article-title": "Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis", "volume": "19", "author": "Sreekanthreddy", "year": "2010", "journal-title": "Cancer Epidemiol Biomarkers Prev"}, {"issue": "3", "key": "key\n\t\t\t\t20170508184906_NOR187C26", "doi-asserted-by": "crossref", "first-page": "833", "DOI": "10.1200/JCO.2002.20.3.833", "article-title": "Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis", "volume": "20", "author": "Shariat", "year": "2002", "journal-title": "J Clin Oncol"}, {"issue": "8", "key": "key\n\t\t\t\t20170508184906_NOR187C27", "doi-asserted-by": "crossref", "first-page": "3013", "DOI": "10.1158/0008-5472.CAN-09-3108", "article-title": "Genetic screen identifies insulin-like growth factor binding protein 5 as a modulator of tamoxifen resistance in breast cancer", "volume": "70", "author": "Ahn", "year": "2010", "journal-title": "Cancer Research"}, {"issue": "5", "key": "key\n\t\t\t\t20170508184906_NOR187C28", "doi-asserted-by": "crossref", "first-page": "1438", "DOI": "10.1158/1078-0432.CCR-06-2245", "article-title": "Insulin-like growth factor binding proteins IGFBP3, IGFBP4, and IGFBP5 predict endocrine responsiveness in patients with ovarian cancer", "volume": "13", "author": "Walker", "year": "2007", "journal-title": "Clin Cancer Res"}, {"issue": "11", "key": "key\n\t\t\t\t20170508184906_NOR187C29", "doi-asserted-by": "crossref", "first-page": "2106", "DOI": "10.1093/carcin/bgn206", "article-title": "Insulin-like growth factor-binding protein-5 (IGFBP-5) acts as a tumor suppressor by inhibiting angiogenesis", "volume": "29", "author": "Rho", "year": "2008", "journal-title": "Carcinogenesis"}, {"issue": "1\u20132", "key": "key\n\t\t\t\t20170508184906_NOR187C30", "doi-asserted-by": "crossref", "first-page": "121", "DOI": "10.1023/A:1006436624862", "article-title": "Growth factors in glioma angiogenesis: FGFs, PDGF, EGF, and TGFs", "volume": "50", "author": "Dunn", "year": "2000", "journal-title": "Journal of Neuro-oncology"}, {"issue": "14", "key": "key\n\t\t\t\t20170508184906_NOR187C31", "doi-asserted-by": "crossref", "first-page": "4783", "DOI": "10.1158/0008-5472.CAN-03-3831", "article-title": "Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis", "volume": "64", "author": "Shih", "year": "2004", "journal-title": "Cancer Research"}, {"issue": "1", "key": "key\n\t\t\t\t20170508184906_NOR187C32", "first-page": "49", "article-title": "Platelet-derived growth factor signaling and human cancer", "volume": "36", "author": "Yu", "year": "2003", "journal-title": "Journal of Biochemistry and Molecular Biology"}, {"issue": "1", "key": "key\n\t\t\t\t20170508184906_NOR187C33", "doi-asserted-by": "crossref", "first-page": "21", "DOI": "10.1016/j.ccr.2008.12.004", "article-title": "PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment", "volume": "15", "author": "Crawford", "year": "2009", "journal-title": "Cancer Cell"}, {"issue": "14", "key": "key\n\t\t\t\t20170508184906_NOR187C34", "doi-asserted-by": "crossref", "first-page": "2800", "DOI": "10.1038/sj.emboj.7600289", "article-title": "VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis", "volume": "23", "author": "Dong", "year": "2004", "journal-title": "The EMBO Journal"}, {"issue": "7223", "key": "key\n\t\t\t\t20170508184906_NOR187C35", "doi-asserted-by": "crossref", "first-page": "809", "DOI": "10.1038/nature07424", "article-title": "A role for VEGF as a negative regulator of pericyte function and vessel maturation", "volume": "456", "author": "Greenberg", "year": "2008", "journal-title": "Nature"}, {"issue": "16", "key": "key\n\t\t\t\t20170508184906_NOR187C36", "doi-asserted-by": "crossref", "first-page": "7241", "DOI": "10.1158/0008-5472.CAN-04-4171", "article-title": "Platelet-derived growth factor-AA is an essential and autocrine regulator of vascular endothelial growth factor expression in non-small cell lung carcinomas", "volume": "65", "author": "Shikada", "year": "2005", "journal-title": "Cancer Research"}, {"issue": "8", "key": "key\n\t\t\t\t20170508184906_NOR187C37", "doi-asserted-by": "crossref", "first-page": "732", "DOI": "10.1593/neo.09408", "article-title": "Platelet-derived growth factor-receptor alpha strongly inhibits melanoma growth in vitro and in vivo", "volume": "11", "author": "Faraone", "year": "2009", "journal-title": "Neoplasia"}], "container-title": ["Neuro-Oncology"], "language": "en", "link": [{"URL": "http://academic.oup.com/neuro-oncology/article-pdf/14/1/93/16663640/nor187.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 8, 23]], "date-time": "2017-08-23T18:10:05Z", "timestamp": 1503511805000}, "score": 10.810045, "issued": {"date-parts": [[2011, 10, 25]]}, "references-count": 37, "journal-issue": {"published-online": {"date-parts": [[2011, 10, 25]]}, "published-print": {"date-parts": [[2012, 1]]}, "issue": "1"}, "URL": "http://dx.doi.org/10.1093/neuonc/nor187", "relation": {"cites": []}, "ISSN": ["1523-5866", "1522-8517"], "issn-type": [{"value": "1522-8517", "type": "print"}, {"value": "1523-5866", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T15:53:53Z", "timestamp": 1574524433444}, "reference-count": 29, "publisher": "Public Library of Science (PLoS)", "issue": "12", "license": [{"URL": "http://creativecommons.org/licenses/by/4.0/", "start": {"date-parts": [[2012, 12, 26]], "date-time": "2012-12-26T00:00:00Z", "timestamp": 1356480000000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": ["www.plosone.org"], "crossmark-restriction": false}, "short-container-title": ["PLoS ONE"], "DOI": "10.1371/journal.pone.0052753", "type": "journal-article", "created": {"date-parts": [[2012, 12, 26]], "date-time": "2012-12-26T22:10:13Z", "timestamp": 1356559813000}, "page": "e52753", "update-policy": "http://dx.doi.org/10.1371/journal.pone.corrections_policy", "source": "Crossref", "is-referenced-by-count": 22, "title": ["Vorinostat Eliminates Multicellular Resistance of Mesothelioma 3D Spheroids via Restoration of Noxa Expression"], "prefix": "10.1371", "volume": "7", "author": [{"given": "Dario", "family": "Barbone", "sequence": "first", "affiliation": []}, {"given": "Priscilla", "family": "Cheung", "sequence": "additional", "affiliation": []}, {"given": "Sailaja", "family": "Battula", "sequence": "additional", "affiliation": []}, {"given": "Sara", "family": "Busacca", "sequence": "additional", "affiliation": []}, {"given": "Steven G.", "family": "Gray", "sequence": "additional", "affiliation": []}, {"given": "Daniel B.", "family": "Longley", "sequence": "additional", "affiliation": []}, {"given": "Raphael", "family": "Bueno", "sequence": "additional", "affiliation": []}, {"given": "David J.", "family": "Sugarbaker", "sequence": "additional", "affiliation": []}, {"given": "Dean A.", "family": "Fennell", "sequence": "additional", "affiliation": []}, {"given": "V. Courtney", "family": "Broaddus", "sequence": "additional", "affiliation": []}], "member": "340", "published-online": {"date-parts": [[2012, 12, 26]]}, "reference": [{"key": "ref1", "doi-asserted-by": "crossref", "first-page": "e174", "DOI": "10.1038/cddis.2011.58", "article-title": "The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance", "volume": "2", "author": "D Barbone", "year": "2011", "journal-title": "Cell Death Dis"}, {"key": "ref2", "doi-asserted-by": "crossref", "first-page": "576", "DOI": "10.1165/rcmb.2007-0460OC", "article-title": "mTOR mediates survival signals in malignant mesothelioma grown as tumor fragment spheroids", "volume": "39", "author": "SM Wilson", "year": "2008", "journal-title": "Am J Respir Cell Mol Biol"}, {"key": "ref3", "doi-asserted-by": "crossref", "first-page": "14", "DOI": "10.1165/rcmb.2008-0320OC", "article-title": "Bcl-2 family proteins contribute to apoptotic resistance in lung cancer multicellular spheroids", "volume": "41", "author": "TM Yang", "year": "2009", "journal-title": "Am J Respir Cell Mol Biol"}, {"key": "ref4", "doi-asserted-by": "crossref", "first-page": "573", "DOI": "10.1023/B:APPT.0000038036.31271.50", "article-title": "Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors", "volume": "9", "author": "F Facchetti", "year": "2004", "journal-title": "Apoptosis"}, {"key": "ref5", "doi-asserted-by": "crossref", "first-page": "275", "DOI": "10.1097/JTO.0b013e3181c5e366", "article-title": "Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials", "volume": "5", "author": "PK Paik", "year": "2010", "journal-title": "J Thorac Oncol"}, {"key": "ref6", "doi-asserted-by": "crossref", "first-page": "1096", "DOI": "10.1016/j.ejca.2011.11.009", "article-title": "Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent", "volume": "48", "author": "JL Hurwitz", "year": "2012", "journal-title": "Eur J Cancer"}, {"key": "ref7", "doi-asserted-by": "crossref", "first-page": "85", "DOI": "10.1038/icb.2011.100", "article-title": "HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications", "volume": "90", "author": "O Khan", "year": "2012", "journal-title": "Immunol Cell Biol"}, {"key": "ref8", "doi-asserted-by": "crossref", "first-page": "2443", "DOI": "10.1182/blood-2011-10-292003", "article-title": "Histone/protein deacetylases and T-cell immune responses", "volume": "119", "author": "T Akimova", "year": "2012", "journal-title": "Blood"}, {"key": "ref9", "doi-asserted-by": "crossref", "first-page": "1466", "DOI": "10.1097/JTO.0b013e318260dfb9", "article-title": "Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma", "volume": "7", "author": "DA Fennell", "year": "2012", "journal-title": "J Thorac Oncol"}, {"key": "ref10", "doi-asserted-by": "crossref", "first-page": "e14640", "DOI": "10.1371/journal.pone.0014640", "article-title": "The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy", "volume": "6", "author": "X Xiang", "year": "2011", "journal-title": "PLoS One"}, {"key": "ref11", "doi-asserted-by": "crossref", "first-page": "473", "DOI": "10.1039/C0AN00609B", "article-title": "High-throughput 3D spheroid culture and drug testing using a 384 hanging drop array", "volume": "136", "author": "YC Tung", "year": "2011", "journal-title": "Analyst"}, {"key": "ref12", "doi-asserted-by": "crossref", "first-page": "1146", "DOI": "10.1038/cdd.2009.32", "article-title": "Malignant pleural mesothelioma cells resist anoikis as quiescent pluricellular aggregates", "volume": "16", "author": "J Daubriac", "year": "2009", "journal-title": "Cell Death Differ"}, {"key": "ref13", "first-page": "2610", "article-title": "p53 and Kirsten-ras mutations in human mesothelioma cell lines", "volume": "52", "author": "RA Metcalf", "year": "1992", "journal-title": "Cancer Res"}, {"key": "ref14", "first-page": "L165", "article-title": "Resistance of pleural mesothelioma cell lines to apoptosis: relation to expression of Bcl-2 and Bax", "volume": "275", "author": "SR Narasimhan", "year": "1998", "journal-title": "Am J Physiol"}, {"key": "ref15", "doi-asserted-by": "crossref", "first-page": "1395", "DOI": "10.1016/0003-4975(94)90090-6", "article-title": "Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma", "volume": "57", "author": "WR Smythe", "year": "1994", "journal-title": "Ann Thorac Surg"}, {"key": "ref16", "doi-asserted-by": "crossref", "first-page": "671", "DOI": "10.1165/rcmb.2007-0205OC", "article-title": "CaSm (LSm-1) overexpression in lung cancer and mesothelioma is required for transformed phenotypes", "volume": "38", "author": "PM Watson", "year": "2008", "journal-title": "Am J Respir Cell Mol Biol"}, {"key": "ref17", "doi-asserted-by": "crossref", "first-page": "13021", "DOI": "10.1074/jbc.M709698200", "article-title": "Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids", "volume": "283", "author": "D Barbone", "year": "2008", "journal-title": "J Biol Chem"}, {"key": "ref18", "doi-asserted-by": "crossref", "first-page": "541", "DOI": "10.1165/rcmb.2004-0355OC", "article-title": "A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance", "volume": "33", "author": "KU Kim", "year": "2005", "journal-title": "Am J Respir Cell Mol Biol"}, {"key": "ref19", "doi-asserted-by": "crossref", "first-page": "402", "DOI": "10.1006/meth.2001.1262", "article-title": "Analysis of relative gene expression data using real-time quantitative PCR and the 2(\u2212Delta Delta C(T)) Method", "volume": "25", "author": "KJ Livak", "year": "2001", "journal-title": "Methods"}, {"key": "ref20", "doi-asserted-by": "crossref", "first-page": "2636", "DOI": "10.1200/JCO.2003.11.136", "article-title": "Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma", "volume": "21", "author": "NJ Vogelzang", "year": "2003", "journal-title": "J Clin Oncol"}, {"key": "ref21", "doi-asserted-by": "crossref", "first-page": "S84", "DOI": "10.1038/onc.2009.46", "article-title": "Noxa: at the tip of the balance between life and death", "volume": "27", "author": "C Ploner", "year": "2008", "journal-title": "Oncogene"}, {"key": "ref22", "doi-asserted-by": "crossref", "first-page": "15016", "DOI": "10.1074/jbc.M109.086231", "article-title": "Perturbation of the Bcl-2 network and an induced Noxa/Bcl-xL interaction trigger mitochondrial dysfunction after DNA damage", "volume": "285", "author": "H Lopez", "year": "2010", "journal-title": "J Biol Chem"}, {"key": "ref23", "doi-asserted-by": "crossref", "first-page": "17682", "DOI": "10.1074/jbc.M110.189092", "article-title": "Noxa/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cells", "volume": "286", "author": "AJ Smith", "year": "2011", "journal-title": "J Biol Chem"}, {"key": "ref24", "doi-asserted-by": "crossref", "first-page": "3956", "DOI": "10.1158/1078-0432.CCR-10-3412", "article-title": "Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters", "volume": "17", "author": "S Xargay-Torrent", "year": "2011", "journal-title": "Clin Cancer Res"}, {"key": "ref25", "doi-asserted-by": "crossref", "first-page": "31", "DOI": "10.1186/1756-8722-2-31", "article-title": "Vorinostat in solid and hematologic malignancies", "volume": "2", "author": "D Siegel", "year": "2009", "journal-title": "J Hematol Oncol"}, {"key": "ref26", "doi-asserted-by": "crossref", "first-page": "129", "DOI": "10.1183/09031936.00037310", "article-title": "Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study", "volume": "37", "author": "A Scherpereel", "year": "2011", "journal-title": "Eur Respir J"}, {"key": "ref27", "doi-asserted-by": "crossref", "first-page": "987", "DOI": "10.1016/j.bcp.2011.11.010", "article-title": "Sensitization of tumor cells by targeting histone deacetylases", "volume": "83", "author": "P Perego", "year": "2012", "journal-title": "Biochem Pharmacol"}, {"key": "ref28", "doi-asserted-by": "crossref", "first-page": "783", "DOI": "10.1158/1078-0432.CCR-11-1166", "article-title": "Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737", "volume": "18", "author": "KM Lucas", "year": "2012", "journal-title": "Clin Cancer Res"}, {"key": "ref29", "doi-asserted-by": "crossref", "first-page": "505", "DOI": "10.4155/fmc.12.3", "article-title": "Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed", "volume": "4", "author": "BE Gryder", "year": "2012", "journal-title": "Future Med Chem"}], "container-title": ["PLoS ONE"], "language": "en", "link": [{"URL": "http://dx.plos.org/10.1371/journal.pone.0052753", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 10, 20]], "date-time": "2018-10-20T05:16:52Z", "timestamp": 1540012612000}, "score": 10.810045, "editor": [{"given": "Keiran", "family": "Smalley", "sequence": "first", "affiliation": []}], "issued": {"date-parts": [[2012, 12, 26]]}, "references-count": 29, "journal-issue": {"published-online": {"date-parts": [[2012, 12, 26]]}, "issue": "12"}, "URL": "http://dx.doi.org/10.1371/journal.pone.0052753", "relation": {"cites": []}, "ISSN": ["1932-6203"], "issn-type": [{"value": "1932-6203", "type": "electronic"}]}], "items-per-page": 20, "query": {"start-index": 0, "search-terms": null}}}